Document:

EX-10.1

 Exhibit 10.1 

2016 STOCK INCENTIVE PLAN 

OF 

KYN THERAPEUTICS INC. 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	Page	 
			
	 1.
	 	Purpose	  	 	1	 
			
	 2.
	 	Eligibility	  	 	1	 
			
	 3.
	 	Administration and Delegation	  	 	1	 
				
		 	(a)	  	Administration by the Board	  	 	1	 
				
		 	(b)	  	Appointment of Committees	  	 	1	 
			
	 4.
	 	Stock Available for Awards	  	 	2	 
				
		 	(a)	  	Number of Shares	  	 	2	 
				
		 	(b)	  	Substitute Awards	  	 	2	 
			
	 5.
	 	Stock Options	  	 	2	 
				
		 	(a)	  	General	  	 	2	 
				
		 	(b)	  	Incentive Stock Options	  	 	2	 
				
		 	(c)	  	Exercise Price	  	 	3	 
				
		 	(d)	  	Duration of Options	  	 	3	 
				
		 	(e)	  	Exercise of Options	  	 	3	 
				
		 	(f)	  	Payment Upon Exercise	  	 	3	 
			
	 6.
	 	Stock Appreciation Rights	  	 	4	 
				
		 	(a)	  	General	  	 	4	 
				
		 	(b)	  	Measurement Price	  	 	4	 
				
		 	(c)	  	Duration of SARs	  	 	4	 
				
		 	(d)	  	Exercise of SARs	  	 	5	 
			
	 7.
	 	Restricted Stock; Restricted Stock Units	  	 	5	 
				
		 	(a)	  	General	  	 	5	 
				
		 	(b)	  	Terms and Conditions for All Restricted Stock Awards	  	 	5	 
				
		 	(c)	  	Additional Provisions Relating to Restricted Stock	  	 	5	 
				
		 	(d)	  	Additional Provisions Relating to Restricted Stock Units	  	 	5	 
			
	 8.
	 	Other Stock-Based Awards	  	 	6	 
				
		 	(a)	  	General	  	 	6	 
				
		 	(b)	  	Terms and Conditions	  	 	6	 
			
	 9.
	 	Adjustments for Changes in Common Stock and Certain Other Events	  	 	6	 
				
		 	(a)	  	Changes in Capitalization	  	 	6	 
				
		 	(b)	  	Reorganization Events	  	 	7	 

									
			
	 10.
	 	General Provisions Applicable to Awards	  	 	9	 
				
		 	(a)	  	Transferability of Awards	  	 	9	 
				
		 	(b)	  	Documentation	  	 	9	 
				
		 	(c)	  	Board Discretion	  	 	9	 
				
		 	(d)	  	Termination of Status	  	 	9	 
				
		 	(e)	  	Withholding	  	 	9	 
				
		 	(f)	  	Amendment of Award	  	 	10	 
				
		 	(g)	  	Conditions on Delivery of Stock	  	 	10	 
				
		 	(h)	  	Acceleration	  	 	10	 
			
	 11.
	 	Miscellaneous	  	 	10	 
				
		 	(a)	  	No Right To Employment or Other Status	  	 	10	 
				
		 	(b)	  	No Rights As Stockholder	  	 	11	 
				
		 	(c)	  	Effective Date and Term of Plan	  	 	11	 
				
		 	(d)	  	Amendment of Plan	  	 	11	 
				
		 	(e)	  	Authorization of Sub-Plans (including Grants to non-U.S. Employees)	  	 	11	 
				
		 	(f)	  	Compliance with Section 409A of the Code	  	 	11	 
				
		 	(g)	  	Limitations on Liability	  	 	12	 
				
		 	(h)	  	Governing Law	  	 	12	 

 2016 STOCK INCENTIVE PLAN 

OF 

KYN THERAPEUTICS INC. 

 

	1.	 Purpose 

The purpose of this 2016 Stock Incentive Plan (the “Plan”) of Kyn Therapeutics Inc., a Delaware corporation (the
“Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by
providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires,
the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations
thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the
Company (the “Board”); provided, however, that such other business ventures shall be limited to entities that, where required by Section 409A of the Code, are eligible issuers of service recipient stock (as defined in
Treas. Reg. Section 1.409A-1(b)(5)(iii)(E), or applicable successor regulation). 
  

	2.	 Eligibility 

All of the Company’s employees, officers and directors, as well as consultants and advisors to the Company (as such terms consultants and
advisors are defined and interpreted for purposes of Rule 701 under the Securities Act of 1933, as amended (the “Securities Act”) (or any successor rule)) are eligible to be granted Awards under the Plan. Each person who is granted
an Award under the Plan is deemed a “Participant.” “Award” means Options (as defined in Section 5), SARs (as defined in Section 6), Restricted Stock (as defined in Section 7), Restricted Stock Units
(as defined in Section 7) and Other Stock-Based Awards (as defined in Section 8). 
  

	3.	 Administration and Delegation 

(a) Administration by the Board. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to
adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it shall deem advisable. The Board may construe and interpret the terms of the Plan and any Award agreements entered into under the Plan. The Board
may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and final judge of such expediency.
All decisions by the Board shall be made in the Board’s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. 

(b) Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the
Plan to one or more committees or subcommittees of the Board (each, a “Committee”). All references in the Plan to the “Board” shall mean the Board or a Committee of the Board to the extent that the Board’s
powers or authority under the Plan have been delegated to such Committee. 

	4.	 Stock Available for Awards 

(a) Number of Shares. Subject to adjustment under Section 9, Awards may be made under the Plan for up to 2,454,545 shares of common
stock, $0.001 par value per share, of the Company (the “Common Stock”), any or all of which Awards may be in the form of Incentive Stock Options (as defined in Section 5(b)). If any Award expires or is terminated, surrendered
or canceled without having been fully exercised, is forfeited in whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual
repurchase right), or results in any Common Stock not being issued, the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a
Participant to exercise an Award or to satisfy tax withholding obligations arising with respect to an Award shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive
Stock Options, the two immediately preceding sentences shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. 

(b) Substitute Awards. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of
property or stock of an entity, the Board may grant Awards in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Substitute Awards may be granted on such terms as the Board deems
appropriate in the circumstances, notwithstanding any limitations on Awards contained in the Plan. Substitute Awards shall not count against the overall share limit set forth in Section 4(a), except as may be required by reason of
Section 422 and related provisions of the Code. 
  

	5.	 Stock Options 

(a) General. The Board may grant options to purchase Common Stock (each, an “Option”) and determine the number of
shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it
considers necessary or advisable. 
 (b) Incentive Stock Options. An Option that the Board intends to be an “incentive
stock option” as defined in Section 422 of the Code (an “Incentive Stock Option”) shall only be granted to employees of Kyn Therapeutics Inc., any of Kyn Therapeutic Inc.’s present or future parent or subsidiary
corporations as defined in Sections 424(e) or (f) of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed consistently with
the requirements of Section 422 of the Code. An Option that is not intended to be an Incentive Stock Option shall be designated a “Nonstatutory Stock Option.” The Company shall have no liability to a Participant,
or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive Stock Option or if the Company converts an Incentive Stock Option to a Nonstatutory Stock Option. 

  
 2 

 (c) Exercise Price. The Board shall establish the exercise price of each Option and
specify the exercise price in the applicable Option agreement. The exercise price shall be not less than 100% of the fair market value per share of Common Stock, as determined by (or in a manner approved by) the Board (“Fair Market
Value”), on the date the Option is granted. “Fair Market Value” of a share of Common Stock for purposes of the Plan will be determined as follows: 

(1) if the Common Stock is not publicly traded, the Board will determine the Fair Market Value for purposes of the Plan using any measure of
value it determines to be appropriate (including, as it considers appropriate, relying on appraisals) in a manner consistent with the valuation principles under Code Section 409A, except as the Board may expressly determine otherwise; 

(2) if the Common Stock trades on a national securities exchange, the closing sale price (for the primary trading session) on the date of
grant; or 
 (3) if the Common Stock does not trade on any such exchange, the average of the closing bid and asked prices as reported by an
authorized OTCBB market data vendor as listed on the OTCBB website (otcbb.com) on the date of grant. 
 For any date that is not a trading
day, the Fair Market Value of a share of Common Stock for such date will be determined by using the closing sale price or average of the bid and asked prices, as appropriate, for the immediately preceding trading day and with the timing in the
formulas above adjusted accordingly. The Board can substitute a particular time of day or other measure of “closing sale price” or “bid and asked prices” if appropriate because of exchange or market procedures or can, in its sole
discretion, use weighted averages either on a daily basis or such longer period as complies with Code Section 409A. 
 The Board has
sole discretion to determine the Fair Market Value for purposes of the Plan, and all Awards are conditioned on the participants’ agreement that the Board’s determination is conclusive and binding even though others might make a different
determination. 
 (d) Duration of Options. Each Option shall be exercisable at such times and subject to such terms and conditions as
the Board may specify in the applicable option agreement; provided, however, that no Option will be granted with a term in excess of 10 years. 

(e) Exercise of Options. 

Options may be exercised by delivery to the Company of a notice of exercise in a form of notice (which may be electronic) approved by the
Company, together with payment in full (in a manner specified in Section 5(f)) of the exercise price for the number of shares for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company as
soon as practicable following exercise. 
 (f) Payment Upon Exercise. Common Stock purchased upon the exercise of an
Option granted under the Plan shall be paid for as follows: 
 (1) in cash or by check, payable to the order of the Company; 

  
 3 

 (2) when the Common Stock is registered under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), except as may otherwise be provided in the applicable Option agreement or approved by the Board, in its sole discretion, by (i) delivery of an irrevocable and unconditional undertaking by a
creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions
to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; 

(3) when the Common Stock is registered under the Exchange Act and to the extent provided for in the applicable Option agreement or approved
by the Board, in its sole discretion, by delivery (either by actual delivery or attestation) of shares of Common Stock owned by the Participant valued at their Fair Market Value, provided (i) such method of payment is then
permitted under applicable law, (ii) such Common Stock, if acquired directly from the Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and
(iii) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements; 
 (4)
to the extent provided for in the applicable Nonstatutory Stock Option agreement or approved by the Board in its sole discretion, by delivery of a notice of “net exercise” to the Company, as a result of which the Participant would pay the
exercise price for the portion of the Option being exercised by cancelling a portion of the Option for such number of shares as is equal to the exercise price divided by the excess of the Fair Market Value on the date of exercise over the Option
exercise price per share. 
 (5) to the extent permitted by applicable law and provided for in the applicable Option agreement or approved
by the Board, in its sole discretion, by (i) delivery of a promissory note of the Participant to the Company on terms determined by the Board, or (ii) payment of such other lawful consideration as the Board may determine; or 

(6) by any combination of the above permitted forms of payment. 
  

	6.	 Stock Appreciation Rights 

(a) General. The Board may grant Awards consisting of stock appreciation rights (“SARs”) entitling the holder, upon
exercise, to receive an amount of Common Stock or cash or a combination thereof (such form to be determined by the Board) determined by reference to appreciation, from and after the date of grant, in the Fair Market Value of a share of Common Stock
over the measurement price established pursuant to Section 6(b). The date as of which such appreciation is determined shall be the exercise date. 

(b) Measurement Price. The Board shall establish the measurement price of each SAR and specify it in the applicable SAR agreement. The
measurement price shall not be less than 100% of the Fair Market Value on the date the SAR is granted. 
 (c) Duration of SARs. Each
SAR shall be exercisable at such times and subject to such terms and conditions as the Board may specify in the applicable SAR agreement; provided, however, that no SAR will be granted with a term in excess of 10 years. 

  
 4 

 (d) Exercise of SARs. SARs may be exercised by delivery to the Company of a notice of
exercise in a form (which may be electronic) approved by the Company, together with any other documents required by the Board. 
  

	7.	 Restricted Stock; Restricted Stock Units 

(a) General. The Board may grant Awards entitling recipients to acquire shares of Common Stock (“Restricted Stock”),
subject to the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions
specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. The Board may also grant Awards entitling the recipient to receive shares of
Common Stock or cash to be delivered at the time such Award vests (“Restricted Stock Units”) (Restricted Stock and Restricted Stock Units are each referred to herein as a “Restricted Stock Award”). 

(b) Terms and Conditions for All Restricted Stock Awards. The Board shall determine the terms and conditions of a Restricted Stock Award,
including the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. 
 (c) Additional Provisions Relating to
Restricted Stock. 
 (1) Dividends. Unless otherwise provided in the applicable Award agreement, any dividends (whether paid
in cash, stock or property) declared and paid by the Company with respect to shares of Restricted Stock (“Accrued Dividends”) shall be paid to the Participant only if and when such shares become free from the restrictions on
transferability and forfeitability that apply to such shares. Each payment of Accrued Dividends will be made no later than the end of the calendar year in which the dividends are paid to stockholders of that class of stock or, if later, the 15th day
of the third month following the lapsing of the restrictions on transferability and the forfeitability provisions applicable to the underlying shares of Restricted Stock. 

(2) Stock Certificates. The Company may require that any stock certificates issued in respect of shares of Restricted Stock, as well as
dividends or distributions paid on such Restricted Stock, shall be deposited in escrow by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the expiration of the applicable restriction periods,
the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to Participant’s Designated Beneficiary. “Designated Beneficiary” means
(i) the beneficiary designated, in a manner determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant’s death or (ii) in the absence of an
effective designation by a Participant, “Designated Beneficiary” means the Participant’s estate. 
 (d) Additional
Provisions Relating to Restricted Stock Units. 
 (1) Settlement. Upon the vesting of and/or lapsing of any other
restrictions (i.e., settlement) with respect to each Restricted Stock Unit, the Participant shall be entitled to receive from the Company one share of Common Stock or (if so provided in the applicable Award agreement) an amount of cash equal to the
Fair Market Value of one share of Common Stock. The 

  
 5 

 
Board may, in its discretion, provide that settlement of Restricted Stock Units shall be deferred, on a mandatory basis or at the election of the Participant in a manner that complies with
Section 409A of the Code. 
 (2) Voting Rights. A Participant shall have no voting rights with respect to any Restricted Stock
Units. 
 (3) Dividend Equivalents. The Award agreement for Restricted Stock Units may provide Participants with the right to receive
an amount equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of Common Stock (“Dividend Equivalents”). Dividend Equivalents may be paid currently or credited to an account for
the Participants, may be settled in cash and/or shares of Common Stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted Stock Units with respect to which paid, in each case to the extent provided in the
applicable Award agreement. 
  

	8.	 Other Stock-Based Awards 

(a) General. Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are
otherwise based on, shares of Common Stock or other property, may be granted hereunder to Participants (“Other Stock-Based Awards”). Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of
other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares of Common Stock or cash, as the Board shall determine. 

(b) Terms and Conditions. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other
Stock-Based Award, including any purchase price applicable thereto. 
  

	9.	 Adjustments for Changes in Common Stock and Certain Other Events 

(a) Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any dividend or distribution to holders of Common Stock other than an ordinary cash dividend, (i) the number and class of securities available
under the Plan, (ii) the number and class of securities and exercise price per share of each outstanding Option, (iii) the share and per-share provisions and the measurement price of each outstanding SAR, (iv) the
number of shares subject to and the repurchase price per share subject to each outstanding Restricted Stock Award and (v) the share and per-share-related provisions and the purchase price, if any, of each outstanding Other Stock-Based
Award, shall be equitably adjusted by the Company (or substituted Awards may be made, if applicable) in the manner determined by the Board. Without limiting the generality of the foregoing, in the event the Company effects a split of the Common
Stock by means of a stock dividend and the exercise price of and the number of shares subject to an outstanding Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an
optionee who exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such
Option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. 

  
 6 

 (b) Reorganization Events. 

(1) Definition. A “Reorganization Event” shall mean: (a) any merger or consolidation of the Company with or into
another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any transfer or disposition of all of the Common
Stock of the Company for cash, securities or other property pursuant to a share exchange or other transaction or (c) any liquidation or dissolution of the Company. 

(2) Consequences of a Reorganization Event on Awards Other than Restricted Stock. 

(i) In connection with a Reorganization Event, the Board may take any one or more of the following actions as to all or any (or any portion
of) outstanding Awards other than Restricted Stock on such terms as the Board determines (except to the extent specifically provided otherwise in an applicable Award agreement or another agreement between the Company and the Participant): (i)
provide that such Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a Participant, provide that all of the
Participant’s unexercised Awards will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant (to the extent then exercisable) within a specified period following the date of such notice,
(iii) provide that outstanding Awards shall become exercisable, realizable, or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv) in the event of a
Reorganization Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the “Acquisition Price”), make or provide for a cash
payment to Participants with respect to each Award held by a Participant equal to (A) the number of shares of Common Stock subject to the vested portion of the Award (after giving effect to any acceleration of vesting that occurs upon or
immediately prior to such Reorganization Event) multiplied by (B) the excess, if any, of (I) the Acquisition Price over (II) the exercise, measurement or purchase price of such Award and any applicable tax
withholdings, in exchange for the termination of such Award, (v) provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the
exercise, measurement or purchase price thereof and any applicable tax withholdings) and (vi) any combination of the foregoing. In taking any of the actions permitted under this Section 9(b)(2), the Board shall not be
obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically. 
 (ii)
Notwithstanding the terms of Section 9(b)(2)(i), in the case of outstanding Restricted Stock Units that are subject to Section 409A of the Code: (i) if the applicable Restricted Stock Unit agreement provides that the
Restricted Stock Units shall be settled upon a “change in control event” within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i), and the Reorganization Event constitutes such a “change in control event”,
then no assumption or substitution shall be permitted pursuant to Section 9(b)(2)(i)(i) and the Restricted 

  
 7 

 
Stock Units shall instead be settled in accordance with the terms of the applicable Restricted Stock Unit agreement; and (ii) the Board may only undertake the actions set forth in
clauses (iii), (iv) or (v) of Section 9(b)(2)(i) if the Reorganization Event constitutes a “change in control event” as defined under Treasury Regulation Section 1.409A-3(i)(5)(i) and such
action is permitted or required by Section 409A of the Code; if the Reorganization Event is not a “change in control event” as so defined or such action is not permitted or required by Section 409A of the Code, and
the acquiring or succeeding corporation does not assume or substitute the Restricted Stock Units pursuant to clause (i) of Section 9(b)(2)(i), then the unvested Restricted Stock Units shall terminate immediately prior to the
consummation of the Reorganization Event without any payment in exchange therefor. 
 (iii) For purposes of Section 9(b)(2)(i)(i), an
Award (other than Restricted Stock) shall be considered assumed if, following consummation of the Reorganization Event, such Award confers the right to purchase or receive pursuant to the terms of such Award, for each share of Common Stock subject
to the Award immediately prior to the consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock
held immediately prior to the consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided,
however, that if the consideration received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding
corporation, provide for the consideration to be received upon the exercise or settlement of the Award to consist solely of such number of shares of common stock of the acquiring or succeeding corporation (or an affiliate thereof) that the Board
determined to be equivalent in value (as of the date of such determination or another date specified by the Board) to the per share consideration received by holders of outstanding shares of Common Stock as a result of the Reorganization Event. 

(3) Consequences of a Reorganization Event on Restricted Stock. Upon the occurrence of a Reorganization Event other than a liquidation
or dissolution of the Company, the repurchase and other rights of the Company with respect to outstanding Restricted Stock shall inure to the benefit of the Company’s successor and shall, unless the Board determines otherwise, apply to the
cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to such Restricted Stock; provided, however, that
the Board may provide for termination or deemed satisfaction of such repurchase or other rights under the instrument evidencing any Restricted Stock or any other agreement between a Participant and the Company, either initially or by amendment. Upon
the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock or any other agreement between a
Participant and the Company, all restrictions and conditions on all Restricted Stock then outstanding shall automatically be deemed terminated or satisfied. 

  
 8 

	10.	 General Provisions Applicable to Awards. 

(a) Transferability of Awards. Awards (or any interest in an Award, including, prior to exercise, any interest in shares of Common Stock
issuable upon exercise of an Option or SAR) shall not be sold, assigned, transferred (including by establishing any short position, put equivalent position (as defined in Rule 16a-1 issued under the Exchange Act) or call equivalent position (as
defined in Rule 16a-1 issued under the Exchange Act)), pledged, hypothecated or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, and, during the life of the Participant, shall be exercisable
only by the Participant; except that Awards, other than Awards subject to Section 409A of the Code, may be transferred to family members (as defined in Rule 701(c)(3) under the Securities Act) through gifts or (other than Incentive Stock
Options) domestic relations orders or to an executor or guardian upon the death of the Participant. The Company shall not be required to recognize any such permitted transfer until such time as such permitted transferee shall deliver to the Company
a written instrument, as a condition to such transfer, in form and substance satisfactory to the Company confirming that such transferee shall be bound by all of the terms and conditions of the Award. References to a Participant, to the extent
relevant in the context, shall include references to authorized transferees. For the avoidance of doubt, nothing contained in this Section 10(a) shall be deemed to restrict a transfer to the Company. 

(b) Documentation. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine. Each
Award may contain terms and conditions in addition to those set forth in the Plan. 
 (c) Board Discretion. Except as otherwise
provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. 

(d) Termination of Status. The Board shall determine the effect on an Award of the disability, death, termination or other cessation of
employment, authorized leave of absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant’s legal representative, conservator, guardian
or Designated Beneficiary, may exercise rights under the Award. 
 (e) Withholding. The Participant must satisfy all
applicable federal, state, and local or other income and employment tax withholding obligations before the Company will deliver stock certificates or otherwise recognize ownership of Common Stock under an Award. The Company may decide to satisfy the
withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the Participant must pay the Company the full amount, if any, required for withholding or have a
broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an Award or at the same time as payment of
the exercise or purchase price unless the Company determines otherwise. If provided for in an Award or approved by the Board in its sole discretion, a Participant may satisfy such tax obligations in whole or in part by delivery (either by actual
delivery or attestation) of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; provided, however, except as 

  
 9 

 
otherwise provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company’s minimum statutory withholding
obligations (based on minimum statutory withholding rates for federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares used to satisfy tax withholding requirements cannot be subject to
any repurchase, forfeiture, unfulfilled vesting or other similar requirements. 
 (f) Amendment of Award. 

(1) The Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting therefor another Award of the
same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option. The Participant’s consent to such action shall be required unless (i) the Board determines
that the action, taking into account any related action, does not materially and adversely affect the Participant’s rights under the Plan or (ii) the change is permitted under Section 9. 

(2) The Board may, without stockholder approval, amend any outstanding Award granted under the Plan to provide an exercise price per share
that is lower than the then-current exercise price per share of such outstanding Award. The Board may also, without stockholder approval, cancel any outstanding award (whether or not granted under the Plan) and grant in substitution therefor new
Awards under the Plan covering the same or a different number of shares of Common Stock and having an exercise price per share lower than the then-current exercise price per share of the cancelled award. 

(g) Conditions on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to
remove restrictions from shares previously issued or delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the Company, (ii) in the opinion of the Company’s counsel, all
other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and regulations and any applicable stock exchange or stock market rules and regulations, and (iii) the
Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. 

(h) Acceleration. The Board may at any time provide that any Award shall become immediately exercisable in whole or in part, free of
some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be. 
  

	11.	 Miscellaneous. 

(a) No Right To Employment or Other Status. No person shall have any claim or right to be granted an Award by virtue of the adoption of
the Plan, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate
its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award. 

  
 10 

 (b) No Rights As Stockholder. Subject to the provisions of the applicable Award, no
Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares. 

(c) Effective Date and Term of Plan. The Plan shall become effective on the date on which it is adopted by the Board. No Awards shall
be granted under the Plan after the expiration of 10 years from the earlier of (i) the date on which the Plan was adopted by the Board or (ii) the date the Plan was approved by the Company’s stockholders, but Awards previously
granted may extend beyond that date. 
 (d) Amendment of Plan. The Board may amend, suspend or terminate the Plan or any portion
thereof at any time; provided that if at any time the approval of the Company’s stockholders is required as to any modification or amendment under Section 422 of the Code or any successor provision with respect to Incentive Stock Options,
the Board may not effect such modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to the Plan adopted in accordance with this Section 11(d) shall apply to, and be binding on the holders
of, all Awards outstanding under the Plan at the time the amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and adversely affect the rights of Participants under the
Plan. 
 (e) Authorization of Sub-Plans (including Grants to non-U.S. Employees). The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable securities, tax or other laws of
various jurisdictions. The Board shall establish such sub-plans by adopting supplements to the Plan containing (i) such limitations on the Board’s discretion under the Plan as the Board deems
necessary or desirable or (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each
supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such supplement. 

(f) Compliance with Section 409A of the Code. Except as provided in individual Award agreements initially or by amendment, if and
to the extent (i) any portion of any payment, compensation or other benefit provided to a Participant pursuant to the Plan in connection with Participant’s employment termination constitutes “nonqualified deferred compensation”
within the meaning of Section 409A of the Code and (ii) the Participant is a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code, in each case as determined by the Company in accordance with its procedures, by which
determinations the Participant (through accepting the Award) agrees that the Participant is bound, such portion of the payment, compensation or other benefit shall not be paid before the day that is six months plus one day after the date of
“separation from service” (as determined under Section 409A of the Code) (the “New Payment Date”), except as Section 409A of the Code may then permit. The aggregate of any payments that otherwise would have been
paid to the Participant during the period between the date of separation from service and the New Payment Date shall be paid to the Participant in a lump sum on such New Payment Date, and any remaining payments will be paid on their original
schedule. 

  
 11 

 The Company makes no representations or warranty and shall have no liability to the Participant or any other
person if any provisions of or payments, compensation or other benefits under the Plan are determined to constitute nonqualified deferred compensation subject to Section 409A of the Code but do not to satisfy the conditions of that section.

 (g) Limitations on Liability. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other
employee, or agent of the Company will be liable to any Participant, former Participant, spouse, beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan, nor will such individual be personally
liable with respect to the Plan because of any contract or other instrument such individual executes in such individual’s capacity as a director, officer, other employee, or agent of the Company. The Company will indemnify and hold harmless
each director, officer, other employee, or agent of the Company to whom any duty or power relating to the administration or interpretation of the Plan has been or will be delegated, against any cost or expense (including attorneys’ fees) or
liability (including any sum paid in settlement of a claim with the Board’s approval) arising out of any act or omission to act concerning the Plan unless arising out of such person’s own fraud or bad faith. 

(h) Governing Law. The provisions of the Plan and all Awards made hereunder shall be governed by and interpreted in accordance with the
laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than
the State of Delaware. 
 * * * * 

  
 12 

 Kyn Therapeutics Inc. 

2016 Stock Incentive Plan 

CALIFORNIA SUPPLEMENT 

Pursuant to Section 11(e) of the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of
Section 25102(o) of the California Law: 
 Any Awards granted under the Plan to a Participant who is a resident of the State of
California on the date of grant (a “California Participant”) shall be subject to the following additional limitations, terms and conditions: 

1. Additional Limitations on Options. 

(a) Maximum Duration of Options. No Options granted to California Participants shall have a term in excess of 10 years measured from the
Option grant date. 
 (b) Minimum Exercise Period Following Termination. Unless a California Participant’s employment is
terminated for cause (as defined by applicable law, the terms of the Plan or option grant or a contract of employment), in the event of termination of employment of such Participant, such Participant shall have the right to exercise an Option, to
the extent that such Participant is entitled to exercise such Option on the date employment terminated, until the earlier of: (i) at least six months from the date of termination, if termination was caused by such Participant’s death or
disability, (ii) at least 30 days from the date of termination, if termination was caused other than by such Participant’s death or disability and (iii) the Option expiration date. 

2. Additional Limitations for Other Stock-Based Awards. The terms of all Awards granted to a California Participant under Section 8 of the Plan
shall comply, to the extent applicable, with Sections 260.140.42, 260.140.45 and 260.140.46 of the California Code of Regulations. 
 3. Additional
Limitations on Timing of Awards. No Award granted to a California Participant shall become exercisable, vested or realizable, as applicable to such Award, unless the Plan has been approved by the holders of a majority of the Company’s
outstanding voting securities by the later of (i) within 12 months before or after the date the Plan was adopted by the Board, or (ii) prior to or within 12 months of the granting of any Award to a California Participant. 

4. Additional Restriction Regarding Recapitalizations, Stock Splits, Etc. For purposes of Section 9 of the Plan, in the event of a stock split,
reverse stock split, stock dividend, recapitalization, combination, reclassification or other distribution of the Company’s securities underlying the Award without the receipt of consideration by the Company, the number of securities
purchasable, and in the case of Options, the exercise price of such Options, must be proportionately adjusted. 
 5. Additional Limitations on
Transferability of Awards. Notwithstanding the provisions of Section 10(a) of the Plan, an Award granted to a California Participant may not be transferred to an executor or guardian upon the disability of the Participant. 

  
 13 

 KYN THERAPEUTICS INC. 

INCENTIVE STOCK OPTION AGREEMENT 

GRANTED UNDER 2016 STOCK INCENTIVE PLAN 

 

	1.	 Grant of Option. 

This Incentive Stock Option Agreement (the “Agreement”) evidences the grant by Kyn Therapeutics Inc., a Delaware corporation
(the “Company”), on [                , 20    ] (the “Grant Date”) to
[                    ], an employee of the Company (the “Participant”), of an option to purchase, in whole or in part, on the terms
provided herein and in the Company’s 2016 Stock Incentive Plan (the “Plan”), a total of [                ] shares (the “Shares”)
of common stock, $0.001 par value per share, of the Company (“Common Stock”) at $[        ] per Share. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on
[                , 20    ] [date is ten years minus one day from grant date] (the “Final Exercise Date”). 

It is intended that the option evidenced by this Agreement shall be an incentive stock option as defined in Section 422 of the Internal
Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). Except as otherwise indicated by the context, the term “Participant”, as used in this option, shall be deemed to include any
person who acquires the right to exercise this option validly under its terms. 
  

	2.	 Vesting Schedule. 

This option will become exercisable (“vest”) as to 25% of the original number of Shares on the first anniversary of the
Vesting Commencement Date (as defined below) and as to an additional 2.0833% of the original number of Shares at the end of each successive month following the first anniversary of the Vesting Commencement Date until the fourth anniversary of the
Vesting Commencement Date. On the fourth anniversary of the Vesting Commencement Date, this option will be exercisable as to all Shares. For purposes of this Agreement, “Vesting Commencement Date” shall mean
[                    ]. 
 The right of
exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the
earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan. 
  

	3.	 Exercise of Option. 

(a) Form of Exercise. Each election to exercise this option shall be accompanied by a completed Notice of Stock Option Exercise in the
form attached hereto as Exhibit A, signed by the Participant, and received by the Company at its principal office, accompanied by this Agreement, and payment in full in the manner provided in the Plan. The Participant may purchase less
than the number of Shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares. 

(b) Continuous Relationship with the Company Required. Except as otherwise provided in this Section 3, this option may not be
exercised unless the Participant, at the time he 

 
or she exercises this option, is, and has been at all times since the Grant Date, an employee or officer of, or consultant or advisor to, the Company or any parent or subsidiary of the Company as
defined in Section 424(e) or (f) of the Code (an “Eligible Participant”). 
 (c) Termination of Relationship
with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate three months after such cessation (but in
no event after the Final Exercise Date), provided that this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant,
prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant
and the Company, the right to exercise this option shall terminate immediately upon such violation. 
 (d) Exercise Period Upon Death or
Disability. If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship
for “cause” as specified in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an
authorized transferee), provided that this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be
exercisable after the Final Exercise Date. 
 (e) Termination for Cause. If, prior to the Final Exercise Date, the Participant’s
employment is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment. If, prior to the Final Exercise Date, the Participant is
given notice by the Company of the termination of his or her employment by the Company for Cause, and the effective date of such employment termination is subsequent to the date of delivery of such notice, the right to exercise this option shall be
suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant’s employment shall not be terminated for Cause as provided in such notice or
(ii) the effective date of such termination of employment (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate upon the effective date of such termination of employment). If the Participant is
party to an employment or severance agreement with the Company that contains a definition of “cause” for termination of employment, “Cause” shall have the meaning ascribed to such term in such agreement. Otherwise,
“Cause” shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any
employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive. The
Participant’s employment shall be considered to have been terminated for Cause if the Company determines, within 30 days after the Participant’s resignation, that termination for Cause was warranted. 

  
 2 

	4.	 Company Right of First Refusal. 

(a) Notice of Proposed Transfer. If the Participant proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by
operation of law or otherwise (collectively, “transfer”) any Shares acquired upon exercise of this option, then the Participant shall first give written notice of the proposed transfer (the “Transfer Notice”) to the
Company. The Transfer Notice shall name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the “Offered Shares”), the price per share and all other material terms and conditions of the
transfer. 
 (b) Company Right to Purchase. For 30 days following its receipt of such Transfer Notice, the Company shall have the
option to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice of such election to
the Participant within such 30-day period. Within 10 days after his or her receipt of such notice, the Participant shall tender to the Company at its principal offices the certificate or certificates
representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company. Promptly
following receipt of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for such Offered Shares; provided that if the terms of payment set forth in the Transfer Notice were
other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and provided further that any delay in making such payment shall not invalidate the
Company’s exercise of its option to purchase the Offered Shares. 
 (c) Shares Not Purchased By Company. If the Company does not
elect to acquire all of the Offered Shares, the Participant may, within the 30-day period following the expiration of the option granted to the Company under subsection (b) above, transfer the Offered
Shares which the Company has not elected to acquire to the proposed transferee, provided that such transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the
above, all Offered Shares transferred pursuant to this Section 4 shall remain subject to the right of first refusal set forth in this Section 4 and such transferee shall, as a condition to such transfer, deliver to the
Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section 4. 

(d) Consequences of Non-Delivery. After the time at which the Offered Shares are required to be
delivered to the Company for transfer to the Company pursuant to subsection (b) above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit the Participant to exercise any of the
privileges or rights of a stockholder with respect to such Offered Shares, but shall, insofar as permitted by law, treat the Company as the owner of such Offered Shares. 

  
 3 

 (e) Exempt Transactions. The following transactions shall be exempt from the
provisions of this Section 4: 
 (1) any transfer of Shares to or for the benefit of any spouse, child or grandchild of the
Participant, or to a trust for their benefit; 
 (2) any transfer pursuant to an effective registration statement filed by the Company under
the Securities Act of 1933, as amended (the “Securities Act”); and 
 (3) the sale of all or substantially all of the
outstanding shares of capital stock of the Company (including pursuant to a merger or consolidation); 
 provided, however, that in the case
of a transfer pursuant to clause (1) above, such Shares shall remain subject to the right of first refusal set forth in this Section 4. 

(f) Assignment of Company Right. The Company may assign its rights to purchase Offered Shares in any particular transaction under this
Section 4 to one or more persons or entities. 
 (g) Termination. The provisions of this Section 4 shall
terminate upon the earlier of the following events: 
 (1) the closing of the sale of shares of Common Stock in an underwritten public
offering pursuant to an effective registration statement filed by the Company under the Securities Act; or 
 (2) the sale of all or
substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and
entities who were beneficial owners of the Company’s voting securities immediately prior to such transaction beneficially own, directly or indirectly, more than 50% (determined on an as-converted basis)
of the outstanding securities entitled to vote generally in the election of directors of the resulting, surviving or acquiring corporation in such transaction). 

(h) No Obligation to Recognize Invalid Transfer. The Company shall not be required (1) to transfer on its books any of the
Shares which shall have been sold or transferred in violation of any of the provisions set forth in this Section 4, or (2) to treat as owner of such Shares or to pay dividends to any transferee to whom any such Shares shall
have been so sold or transferred. 
 (i) Superseding ROFR Provision. Notwithstanding the provisions of subsections 4(a) through 4(h)
above, if at any time the Participant and the Company are parties to a separate agreement containing a right of first refusal provision in favor of the Company that applies to transfers of the Shares (a “Superseding ROFR
Provision”), the terms of such Superseding ROFR Provision will control in lieu of those of subsections 4(a) through 4(h) above and compliance with such Superseding ROFR Provision shall be deemed compliance with subsections 4(a) through 4(h)
above. 

  
 4 

 (j) Legends. The certificate representing Shares shall bear a legend substantially in
the following form (in addition to, or in combination with, any legend required by applicable federal and state securities laws and agreements relating to the transfer of the Company securities): 

“The shares represented by this certificate are subject to a right of first refusal in favor of the Company, as provided in a certain
stock option agreement with the Company.” 
  

	5.	 Agreement in Connection with Initial Public Offering. 

The Participant agrees not to, without the prior written consent of the managing underwriter, during the period commencing on the date of the
final prospectus relating to the Company’s initial public offering (the “IPO”) of Common Stock or any other equity securities under the Securities Act on a registration statement on Form
S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (l80) days in the case of the
IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports; and (2) analyst recommendations and opinions,
including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), or ninety (90) days in the case of any registration other than the IPO, or such other
period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited
to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or other shares of the Company’s capital stock (the “Capital Stock”) (whether such shares
or any such securities are then owned by the Participant or are thereafter acquired); or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Capital
Stock, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Capital Stock or other securities, in cash or otherwise. The foregoing provisions of this Section 5 shall not apply to the sale
of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Participant or the family members of the Participant, provided that the trustee of the
trust agrees to be bound in writing by the restrictions set forth herein. 
  

	6.	 Tax Matters. 

(a) Withholding. No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company,
or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option. 

(b) Disqualifying Disposition. If the Participant disposes of Shares acquired upon exercise of this option within two years from the
Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such disposition. 

  
 5 

	7.	 Transfer Restrictions. 

(a) This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation
of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. 

(b) The Participant agrees that he or she will not transfer any Shares issued pursuant to the exercise of this option unless the transferee,
as a condition to such transfer, delivers to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of Section 4 and Section 5; provided that such a written
confirmation shall not be required with respect to (1) Section 4 after such provision has terminated in accordance with Section 4(g) or (2) Section 5 after the completion of the lock-up period in connection with the Company’s initial underwritten public offering. 
  

	8.	 Provisions of the Plan. 

This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is
furnished to the Participant with this option. 
 [Remainder of Page Intentionally Left Blank] 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. The Participant hereby accepts the foregoing option and agrees to the terms and conditions thereof. The Participant hereby acknowledges receipt of a copy of the Company’s 2016 Stock Incentive Plan. 

 

			
	COMPANY:
	
	Kyn Therapeutics Inc.
		
	By:	 	  

		 	Name:
		 	Title:

  

			
	PARTICIPANT:
		
	By:	 	  

		 	[Name]
		
	Address:	 	[                    ]
		 	[                    ]

  

			
	SPOUSAL CONSENT:1
		
	By:	 	  

		 	Name:
		
	Address:	 	[                    ]
		 	[                    ]

  

	1	 If the Participant resides in a community property state, it is desirable to have the Participant’s spouse
also accept the option. The following are community property states: Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, and Washington. Although Wisconsin is not formally a community property state, it has laws governing the division
of marital property similar to community property states and it may be desirable to have a Wisconsin Participant’s spouse accept the option. 

  
 SIGNATURE PAGE TO
INCENTIVE STOCK OPTION STATEMENT 

 EXHIBIT A 

NOTICE OF STOCK OPTION EXERCISE 

[DATE]1 

Kyn Therapeutics Inc. 
 6405 Williams Ridge Way 

Austin, TX 78731 
 Attention: Treasurer 

Dear Sir or Madam: 
 I am the holder of a
Nonstatutory Stock Option granted to me under the Kyn Therapeutics Inc. (the “Company”) 2016 Stock Incentive Plan on [                ]2 for the purchase of [                ]3 shares of Common Stock of
the Company at a purchase price of $[                ]4 per share. 

I hereby exercise my option to purchase [                ]5 shares of Common Stock (the “Shares”), for which I have enclosed [                ]6 in the amount of [                ]7. Please register my stock
certificate as follows: 
  

					
	Name(s):	  	
                  
                                         
  8
 	  	
		  	  
	  	
			
	Address:	  	  
	  	
			
		  	  
	  	

 I represent, warrant and covenant as follows: 

 

	1 	 Enter date of exercise. 

	2 	 Enter the date of grant. 

	3 	 Enter the total number of shares of Common Stock for which the option was granted. 

	4 	 Enter the option exercise price per share of Common Stock. 

	5 	 Enter the number of shares of Common Stock to be purchased upon exercise of all or part of the option.

	6 	 Enter “cash”, “personal check” or if permitted by the option or Plan, “stock
certificates No. XXXX and XXXX”. 

	7 	 Enter the dollar amount (price per share of Common Stock times the number of shares of Common Stock to be
purchased), or the number of shares tendered. Fair market value of shares tendered, together with cash or check, must cover the purchase price of the shares issued upon exercise. 

	8 	 Enter name(s) to appear on stock certificate in one of the following formats: (a) your name only (i.e.,
John Doe); (b) your name and other name (i.e., John Doe and Jane Doe, Joint Tenants with Right to Survivorship); or for Nonstatutory Stock Options only, (c) a child’s name, with you as custodian (i.e., Jane Doe, Custodian for Tommy
Doe). Note: There may be income and/or gift tax consequences for registering shares in a child’s name. 

 1. I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in
connection with, any distribution of the Shares in violation of the Securities Act of 1933 (the “Securities Act”), or any rule or regulation under the Securities Act. 

2. I have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to
evaluate the merits and risks of my investment in the Company. 
 3. I have sufficient experience in business, financial and investment matters to be able
to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase. 
 4. I can afford a
complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period. 
 5. I understand that
(i) the Shares have not been registered under the Securities Act and are “restricted securities” within the meaning of Rule 144 under the Securities Act, (ii) the Shares cannot be sold, transferred or otherwise disposed of unless
they are subsequently registered under the Securities Act or an exemption from registration is then available; (iii) in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not
be available unless a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv) there is now no
registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act. 

Very truly yours, 
  

			
	  

	[Name]	 	

  
 9 

 KYN THERAPEUTICS INC. 

NONSTATUTORY STOCK OPTION AGREEMENT 

GRANTED UNDER 2016 STOCK INCENTIVE PLAN 

 

	1.	 Grant of Option. 

This Nonstatutory Stock Option Agreement (the “Agreement”) evidences the grant by Kyn Therapeutics Inc., a Delaware
corporation (the “Company”), on [                         ,
20        ] (the “Grant Date”) to [                ], an employee, consultant or director of the Company (the
“Participant”), of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s 2016 Stock Incentive Plan (the “Plan”), a total of
[                ] shares (the “Shares”) of common stock, $0.001 par value per share, of the Company (“Common Stock”) at
$[                ] per Share. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on
[                         , 20        ] [date is ten years minus one day from grant
date] (the “Final Exercise Date”). 
 It is intended that the option evidenced by this Agreement shall not be an incentive
stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). Except as otherwise indicated by the context, the term
“Participant”, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms. 
  

	2.	 Vesting Schedule. 

This option will become exercisable (“vest”) as to 25% of the original number of Shares on the first anniversary of the
Vesting Commencement Date (as defined below) and as to an additional 2.0833% of the original number of Shares at the end of each successive month following the first anniversary of the Vesting Commencement Date until the fourth anniversary of the
Vesting Commencement Date. On the fourth anniversary of the Vesting Commencement Date, this option will be exercisable as to all Shares. For purposes of this Agreement, “Vesting Commencement Date” shall mean
[                ]. 
 The right of exercise shall be
cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final
Exercise Date or the termination of this option under Section 3 hereof or the Plan. 
  

	3.	 Exercise of Option. 

(a) Form of Exercise. Each election to exercise this option shall be accompanied by a completed Notice of Stock Option Exercise in the
form attached hereto as Exhibit A, signed by the Participant, and received by the Company at its principal office, accompanied by this Agreement, and payment in full in the manner provided in the Plan. The Participant may purchase less than
the number of Shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares. 

 (b) Continuous Relationship with the Company Required. Except as otherwise provided
in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer or director of, or consultant or advisor to, the
Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an “Eligible Participant”). 

(c) Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except
as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), provided that this option shall be exercisable only
to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the
non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this
option shall terminate immediately upon such violation. 
 (d) Exercise Period Upon Death or Disability. If the Participant dies or
becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for “cause” as specified in paragraph
(e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), provided that this
option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date. 

(e) Termination for Cause. If, prior to the Final Exercise Date, the Participant’s employment or other relationship with
the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other relationship. If, prior to the Final Exercise
Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other termination is subsequent to the date of the delivery
of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant’s employment or other
relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the
preceding sentence, terminate immediately upon the effective date of such termination of employment or other relationship). If the Participant is party to an employment, consulting or severance agreement with the Company that contains a definition
of “cause” for termination of employment or other relationship, “Cause” shall have the meaning ascribed to such term in such agreement. Otherwise, “Cause” shall mean willful misconduct by the Participant or willful
failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure,
non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive. The

  
 2 

 
Participant’s employment or other relationship shall be considered to have been terminated for “Cause” if the Company determines, within 30 days after the Participant’s
resignation, that termination for Cause was warranted. 
  

	4.	 Company Right of First Refusal. 

(a) Notice of Proposed Transfer. If the Participant proposes to sell, assign, transfer, pledge, hypothecate or otherwise dispose
of, by operation of law or otherwise (collectively, “transfer”) any Shares acquired upon exercise of this option, then the Participant shall first give written notice of the proposed transfer (the “Transfer Notice”) to the
Company. The Transfer Notice shall name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the “Offered Shares”), the price per share and all other material terms and conditions of the
transfer. 
 (b) Company Right to Purchase. For 30 days following its receipt of such Transfer Notice, the Company shall have the
option to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice of such election to
the Participant within such 30-day period. Within 10 days after his or her receipt of such notice, the Participant shall tender to the Company at its principal offices the certificate or certificates
representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly endorsed stock powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company. Promptly
following receipt of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the purchase price for such Offered Shares; provided that if the terms of payment set forth in the Transfer Notice were
other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice; and provided further that any delay in making such payment shall not invalidate the
Company’s exercise of its option to purchase the Offered Shares. 
 (c) Shares Not Purchased By Company. If the Company does not
elect to acquire all of the Offered Shares, the Participant may, within the 30-day period following the expiration of the option granted to the Company under subsection (b) above, transfer the
Offered Shares which the Company has not elected to acquire to the proposed transferee, provided that such transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice.
Notwithstanding any of the above, all Offered Shares transferred pursuant to this Section 4 shall remain subject to the right of first refusal set forth in this Section 4 and such transferee shall, as a condition to such
transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Section 4. 

(d) Consequences of Non-Delivery. After the time at which the Offered Shares are required to be
delivered to the Company for transfer to the Company pursuant to subsection (b) above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit the Participant to exercise any of the
privileges or rights of a stockholder with respect to such Offered Shares, but shall, insofar as permitted by law, treat the Company as the owner of such Offered Shares. 

  
 3 

 (e) Exempt Transactions. The following transactions shall be exempt from the
provisions of this Section 4: 
 (1) any transfer of Shares to or for the benefit of any spouse, child or grandchild of the
Participant, or to a trust for their benefit; 
 (2) any transfer pursuant to an effective registration statement filed by the Company under
the Securities Act of 1933, as amended (the “Securities Act”); and 
 (3) the sale of all or substantially all of the
outstanding shares of capital stock of the Company (including pursuant to a merger or consolidation); 
 provided, however, that in the case
of a transfer pursuant to clause (1) above, such Shares shall remain subject to the right of first refusal set forth in this Section 4. 

(f) Assignment of Company Right. The Company may assign its rights to purchase Offered Shares in any particular transaction under this
Section 4 to one or more persons or entities. 
 (g) Termination. The provisions of this Section 4 shall
terminate upon the earlier of the following events: 
 (1) the closing of the sale of shares of Common Stock in an underwritten public
offering pursuant to an effective registration statement filed by the Company under the Securities Act; or 
 (2) the sale of all or
substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and
entities who were beneficial owners of the Company’s voting securities immediately prior to such transaction beneficially own, directly or indirectly, more than 50% (determined on an as-converted basis) of the outstanding securities entitled to
vote generally in the election of directors of the resulting, surviving or acquiring corporation in such transaction). 
 (h) No
Obligation to Recognize Invalid Transfer. The Company shall not be required (1) to transfer on its books any of the Shares which shall have been sold or transferred in violation of any of the provisions set forth in this
Section 4, or (2) to treat as owner of such Shares or to pay dividends to any transferee to whom any such Shares shall have been so sold or transferred. 

(i) Superseding ROFR Provision. Notwithstanding the provisions of subsections 4(a) through 4(h) above, if at any time the Participant
and the Company are parties to a separate agreement containing a right of first refusal provision in favor of the Company that applies to transfers of the Shares (a “Superseding ROFR Provision”), the terms of such Superseding ROFR
Provision will control in lieu of those of subsections 4(a) through 4(h) above and compliance with such Superseding ROFR Provision shall be deemed compliance with subsections 4(a) through 4(h) above. 

  
 4 

 (j) Legends. The certificate representing Shares shall bear a legend substantially in
the following form (in addition to, or in combination with, any legend required by applicable federal and state securities laws and agreements relating to the transfer of the Company securities): 

“The shares represented by this certificate are subject to a right of first refusal in favor of the Company, as provided in a certain
stock option agreement with the Company.” 
  

	5.	 Agreement in Connection with Initial Public Offering. 

The Participant agrees not to, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus
relating to the Company’s initial public offering (the “IPO”) of Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (l80) days in the case of the IPO, or such other period as may be requested
by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports; and (2) analyst recommendations and opinions, including, but not limited to, the restrictions
contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), or ninety (90) days in the case of any registration other than the IPO, or such other period as may be requested by the Company or an
underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule
2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or other shares of the Company’s capital stock (the “Capital Stock”) (whether such shares or any such securities are then owned by the
Participant or are thereafter acquired); or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Capital Stock, whether any such transaction described
in clause (a) or (b) above is to be settled by delivery of Capital Stock or other securities, in cash or otherwise. The foregoing provisions of this Section 5 shall not apply to the sale of any shares to an underwriter pursuant to an
underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Participant or the family members of the Participant, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein. 
 6. Withholding. 

No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision
satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option. 
 7.
Transfer Restrictions. 
 (a) This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant,
either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. 

  
 5 

 (b) The Participant agrees that he or she will not transfer any Shares issued pursuant to
the exercise of this option unless the transferee, as a condition to such transfer, delivers to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of Section 4 and
Section 5; provided that such a written confirmation shall not be required with respect to (1) Section 4 after such provision has terminated in accordance with Section 4(g) or (2) Section 5 after the completion of the lock-up period in connection with the Company’s initial underwritten public offering. 
  

	8.	 Provisions of the Plan. 

This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is
furnished to the Participant with this option. 
 [Remainder of Page Intentionally Left Blank] 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
first above written. The Participant hereby accepts the foregoing option and agrees to the terms and conditions thereof. The Participant hereby acknowledges receipt of a copy of the Company’s 2016 Stock Incentive Plan. 

 

							
	COMPANY:
	
	Kyn Therapeutics Inc.
		
	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

	
	PARTICIPANT:
		
	By:	 	  

		 	[Name]	 	
	Address:	 		 	[                    ]
		 		 	[                    ]
	
	SPOUSAL CONSENT:10
	By:	 	  

		 	Name:	 	
	Address:	 		 	[                    ]
		 		 	[                    ]

  

	10 	 If the Participant resides in a community property state,
it is desirable to have the Participant’s spouse also accept the option. The following are community property states: Arizona, California, Idaho, Louisiana, Nevada, New Mexico, Texas, and Washington. Although Wisconsin is not formally a
community property state, it has laws governing the division of marital property similar to community property states and it may be desirable to have a Wisconsin Participant’s spouse accept the option. 

  
 SIGNATURE PAGE TO
NONSTATUTORY STOCK OPTION AGREEMENT 

 EXHIBIT A 

NOTICE OF STOCK OPTION EXERCISE 

[DATE]1 

Kyn Therapeutics Inc. 
 6405 Williams Ridge Way 

Austin, TX 78731 
 Attention: Treasurer 

Dear Sir or Madam: 
 I am the holder of an
Incentive Stock Option granted to me under the Kyn Therapeutics Inc. (the “Company”) 2016 Stock Incentive Plan on
[                    ]2 for the purchase of
[                    ]3 shares of Common Stock of the Company at a purchase price of
$[                    ]4 per share. 

I hereby exercise my option to purchase
[                    ]5 shares of Common Stock (the “Shares”), for which I have
enclosed [                    ]6 in the amount of
[                    ]7. Please register my stock certificate as follows: 

 

					
			
	Name(s):	  	  8
 	  	
		  	  
	  	
			
	Address:	  	  
	  	
			
		  	  
	  	

 I represent, warrant and covenant as follows: 

 

	1 	 Enter date of exercise. 

	2 	 Enter the date of grant. 

	3 	 Enter the total number of shares of Common Stock for which the option was granted. 

	4 	 Enter the option exercise price per share of Common Stock. 

	5 	 Enter the number of shares of Common Stock to be purchased upon exercise of all or part of the option.

	6 	 Enter “cash”, “personal check” or if permitted by the option or Plan, “stock
certificates No. XXXX and XXXX”. 

	7 	 Enter the dollar amount (price per share of Common Stock times the number of shares of Common Stock to be
purchased), or the number of shares tendered. Fair market value of shares tendered, together with cash or check, must cover the purchase price of the shares issued upon exercise. 

	8 	 Enter name(s) to appear on stock certificate in one of the following formats: (a) your name only (i.e.,
John Doe); (b) your name and other name (i.e., John Doe and Jane Doe, Joint Tenants with Right to Survivorship); or for Nonstatutory Stock Options only, (c) a child’s name, with you as custodian (i.e., Jane Doe, Custodian for Tommy
Doe). Note: There may be income and/or gift tax consequences for registering shares in a child’s name. 

 1. I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in
connection with, any distribution of the Shares in violation of the Securities Act of 1933 (the “Securities Act”), or any rule or regulation under the Securities Act. 

2. I have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to
evaluate the merits and risks of my investment in the Company. 
 3. I have sufficient experience in business, financial and investment matters to be able
to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase. 
 4. I can afford a
complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period. 
 5. I understand that
(i) the Shares have not been registered under the Securities Act and are “restricted securities” within the meaning of Rule 144 under the Securities Act, (ii) the Shares cannot be sold, transferred or otherwise disposed of unless
they are subsequently registered under the Securities Act or an exemption from registration is then available; (iii) in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not
be available unless a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv) there is now no
registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act. 

Very truly yours, 
  

	
	  

	[Name]

  
 9 

 [NOTE: UNLESS THE SHARES ARE FULLY VESTED UPON GRANT, 

IT IS GENERALLY ADVISABLE FOR THE PARTICIPANT TO FILE 83(B) ELECTION.] 

KYN THERAPEUTICS INC. 

RESTRICTED STOCK AGREEMENT 

GRANTED UNDER 2016 STOCK INCENTIVE PLAN 

This Restricted Stock Agreement (the “Agreement”) is made this [    ] day of
[                         ], 20[        ], between Kyn Therapeutics Inc., a Delaware
corporation (the “Company”), and [                ] (the “Participant”). 

For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows: 

 

	1.	 Purchase of Shares. 

The Company shall issue and sell to the Participant, and the Participant shall purchase from the Company, subject to the terms and conditions
set forth in this Agreement and in the Company’s 2016 Stock Incentive Plan (the “Plan”), [                ] shares (the “Shares”)
of common stock, $0.001 par value, of the Company (“Common Stock”), at a purchase price of $[                ] per share. The aggregate purchase price
for the Shares shall be paid by the Participant by check payable to the order of the Company or such other method as may be acceptable to the Company. Upon receipt by the Company of payment for the Shares, the Company shall issue to the Participant
one or more certificates in the name of the Participant for that number of Shares purchased by the Participant. The Participant agrees that the Shares shall be subject to the purchase options set forth in Sections 3 and 6 of this Agreement and the
restrictions on transfer set forth in Section 5 of this Agreement. 
  

	2.	 Certain Definitions. 

(a) “Change in Control” shall mean the sale of all or substantially all of the outstanding shares of capital stock, assets or
business of the Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were beneficial owners of the Company’s voting securities
immediately prior to such transaction beneficially own, directly or indirectly, more than 50% (determined on an as-converted basis) of the outstanding securities entitled to vote generally in the election of
directors of the resulting, surviving or acquiring corporation in such transaction). 
 (b) “Service” shall mean employment
by or the provision of services to the Company or a parent or subsidiary thereof as an advisor, officer, consultant or member of the Board of Directors. 

(c) “Vesting Commencement Date” shall mean
[                ]. 

	3.	 Purchase Option. 

(a) In the event that the Participant ceases to provide Service for any reason or no reason, with or without cause, prior to the [fourth (4th)]
anniversary of the Vesting Commencement Date, the Company shall have the right and option (the “Purchase Option”) to purchase from the Participant, for a sum of
$[                ] per share (the “Option Price”), some or all of the Shares as set forth herein. 

(b) All of the Shares shall initially be subject to the Purchase Option. The Participant shall acquire a vested interest in, and the
Company’s Purchase Option shall accordingly lapse with respect to, (i) twenty-five percent (25%) of the Shares upon Participant’s completion of one (1) year of Service measured from the Vesting Commencement Date and
(ii) the balance of the Shares in a series of successive equal monthly installments of [1/48] of the Shares upon Participant’s completion of each additional month of Service over the
[thirty-six (36)-month] period measured from the first anniversary of the Vesting Commencement Date. 
  

	4.	 Exercise of Purchase Option and Closing. 

(a) The Company may exercise the Purchase Option by delivering or mailing to the Participant (or the Participant’s estate), within 180
days after the termination of the Service of the Participant, a written notice of exercise of the Purchase Option. Such notice shall specify the number of Shares to be purchased. If and to the extent the Purchase Option is not so exercised by the
giving of such a notice within such 180-day period, the Purchase Option shall automatically expire and terminate effective upon the expiration of such 180-day period.

 (b) Within ten (10) days after delivery to the Participant of the Company’s notice of the exercise of the Purchase Option
pursuant to subsection (a) above, the Participant (or the Participant’s estate) shall, pursuant to the provisions of the Joint Escrow Instructions referred to in Section 8 below, tender to the Company at its principal offices the
certificate or certificates representing the Shares that the Company has elected to purchase in accordance with the terms of this Agreement, duly endorsed in blank or with duly endorsed stock powers attached thereto, all in form suitable for the
transfer of such Shares to the Company. Promptly following its receipt of such certificate or certificates, the Company shall pay to the Participant the aggregate Option Price for such Shares (provided that any delay in making such payment shall not
invalidate the Company’s exercise of the Purchase Option with respect to such Shares). 
 (c) After the time at which any Shares are
required to be delivered to the Company for transfer to the Company pursuant to subsection (b) above, the Company shall not pay any dividend to the Participant on account of such Shares or permit the Participant to exercise any of the
privileges or rights of a stockholder with respect to such Shares, but shall, in so far as permitted by law, treat the Company as the owner of such Shares. 

(d) The Option Price may be payable, at the option of the Company, in cancellation of all or a portion of any outstanding indebtedness of the
Participant to the Company or in cash (by check) or both. 
 (e) The Company shall not purchase any fraction of a Share upon exercise of the
Purchase Option, and any fraction of a Share resulting from a computation made pursuant to Section 3 of this Agreement shall be rounded to the nearest whole Share (with any one-half Share being rounded
upward). 

  
 2 

 (f) The Company may assign its Purchase Option to one or more persons or entities. 

 

	5.	 Restrictions on Transfer. 

(a) The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise
(collectively “transfer”) any Shares, or any interest therein, that are subject to the Purchase Option, except that the Participant may transfer such Shares (i) for bona fide estate planning purposes, either during the
Participant’s lifetime or on death by will or intestacy to his spouse, child (natural or adopted), or any other direct lineal descendant (or his or her spouse), or any other relative approved by a majority of the board of directors of the
Company (each of the foregoing, “Approved Relatives”), or any custodian or trustee of any trust, partnership or limited liability company for the benefit of, or the ownership interest of which are owned wholly by the Participant or
any such Approved Relatives; provided that such Shares shall remain subject to this Agreement (including without limitation the restrictions on transfer set forth in this Section 5, the Purchase Option and the right of
first refusal set forth in Section 6) and such permitted transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of
this Agreement or (ii) as part of the sale of all or substantially all of the shares of capital stock of the Company (including pursuant to a merger or consolidation); provided that, in accordance with the Plan, the
securities or other property received by the Participant in connection with such transaction shall remain subject to this Agreement. 
 (b)
The Participant shall not transfer any Shares, or any interest therein, that are no longer subject to the Purchase Option, except in accordance with Section 6 below (or, if applicable, in accordance with a Superceding ROFR Provision (as defined
below)). In connection with any such transfer, such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement.

  

	6.	 Right of First Refusal. 

(a) If the Participant proposes to transfer any Shares that are no longer subject to the Purchase Option (either because they are free from the
Purchase Option pursuant to Section 3 or because the Purchase Option expired unexercised pursuant to Section 4), then the Participant shall first give written notice of the proposed transfer (the “Transfer Notice”)
to the Company. The Transfer Notice shall name the proposed transferee and state the number of such Shares the Participant proposes to transfer (the “Offered Shares”), the price per share and all other material terms and conditions
of the transfer. 
 (b) For 30 days following its receipt of such Transfer Notice, the Company shall have the option to purchase all or part
of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice of such election to the Participant within such 30-day period. Within 10 days after the Participant’s receipt of such notice, the Participant shall tender to the Company 

  
 3 

 
at its principal offices the certificate or certificates representing the Offered Shares to be purchased by the Company, duly endorsed in blank by the Participant or with duly endorsed stock
powers attached thereto, all in a form suitable for transfer of the Offered Shares to the Company. Promptly following receipt of such certificate or certificates, the Company shall deliver or mail to the Participant a check in payment of the
purchase price for such Offered Shares; provided that if the terms of payment set forth in the Transfer Notice were other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were
set forth in the Transfer Notice; and provided further that any delay in making such payment shall not invalidate the Company’s exercise of its option to purchase the Offered Shares. 

(c) If the Company does not elect to acquire all of the Offered Shares, the Participant may, within the
30-day period following the expiration of the option granted to the Company under subsection (b) above, transfer the Offered Shares which the Company has not elected to acquire to the proposed transferee,
provided that such transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the above, all Offered Shares transferred pursuant to this
Section 6 shall remain subject to this Agreement (including without limitation the restrictions on transfer set forth in Section 5 and the right of first refusal set forth in this Section 6) and such transferee
shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement. 

(d) After the time at which the Offered Shares are required to be delivered to the Company for transfer to the Company pursuant to
subsection (b) above, the Company shall not pay any dividend to the Participant on account of such Offered Shares or permit the Participant to exercise any of the privileges or rights of a stockholder with respect to such Offered Shares, but
shall, insofar as permitted by law, treat the Company as the owner of such Offered Shares. 
 (e) The following transactions shall be exempt
from the provisions of this Section 6: 
 (1) a transfer of Shares to or for the benefit of any Approved Relatives, or to a trust
established solely for the benefit of the Participant and/or Approved Relatives; 
 (2) any transfer pursuant to an effective registration
statement filed by the Company under the Securities Act of 1933, as amended (the “Securities Act”); and 
 (3) the sale of
all or substantially all of the outstanding shares of capital stock of the Company (including pursuant to a merger or consolidation); 
 provided,
however, that in the case of a transfer pursuant to clause (1) above, such Shares shall remain subject to this Agreement (including without limitation the restrictions on transfer set forth in Section 5 and the right of first refusal set
forth in this Section 6) and such transferee shall, as a condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement. 

(f) The Company may assign its rights to purchase Offered Shares in any particular transaction under this Section 6 to one or more
persons or entities. 

  
 4 

 (g) The provisions of this Section 6 shall terminate upon the earlier of the following
events: 
 (1) the closing of the sale of shares of Common Stock in an underwritten public offering pursuant to an effective registration
statement filed by the Company under the Securities Act; or 
 (2) a Change in Control. 

(h) The Company shall not be required (1) to transfer on its books any of the Shares which shall have been sold or transferred in
violation of any of the provisions set forth in this Agreement, or (2) to treat as owner of such Shares or to pay dividends to any transferee to whom any such Shares shall have been so sold or transferred. 

(i) Notwithstanding the provisions of subsections 6(a) through 6(h) above, if at any time the Participant and the Company are parties to a
separate agreement containing a right of first refusal provision in favor of the Company that applies to transfers of the Shares (a “Superseding ROFR Provision”), the terms of such Superseding ROFR Provision will control in lieu of
those of subsections 6(a) through 6(h) above and compliance with such Superseding ROFR Provision shall be deemed compliance with subsections 6(a) through 6(h) above. 
  

	7.	 Agreement in Connection with Initial Public Offering. 

The Participant agrees not to, without the prior written consent of the managing underwriter, during the period commencing on the date of the
final prospectus relating to the Company’s initial public offering (the “IPO”) of Common Stock or any other equity securities under the Securities Act on a registration statement on Form
S-1 or Form S-3, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (l80) days in the case of the
IPO, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports; and (2) analyst recommendations and opinions,
including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), or ninety (90) days in the case of any registration other than the IPO, or such other
period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited
to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (a) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares or other shares of the Company’s capital stock (the “Capital Stock”) (whether such shares
or any such securities are then owned by the Participant or are thereafter acquired); or (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Capital
Stock, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Capital Stock or other securities, in cash or otherwise. The foregoing provisions of this Section 7 shall not apply to the sale
of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Participant or the family members of the Participant, provided that the trustee of the trust
agrees to be bound in writing by the restrictions set forth herein. 

  
 5 

	8.	 Escrow. 

The Participant shall, upon the execution of this Agreement, execute Joint Escrow Instructions in the form attached to this Agreement as
Exhibit A. The Joint Escrow Instructions shall be delivered to the Secretary of the Company, as escrow agent thereunder. The Participant shall deliver to such escrow agent a stock assignment duly endorsed in blank, in the
form attached to this Agreement as Exhibit B, and hereby instructs the Company to deliver to such escrow agent, on behalf of the Participant, the certificate(s) evidencing the Shares issued hereunder. Such materials shall
be held by such escrow agent pursuant to the terms of such Joint Escrow Instructions. 
  

	9.	 Restrictive Legends. 

All certificates representing Shares shall have affixed thereto legends in substantially the following form, in addition to any other legends
that may be required under federal or state securities laws: 
 “The shares of stock represented by this certificate are subject to
restrictions on transfer and an option to purchase set forth in a certain Restricted Stock Agreement between the corporation and the registered owner of these shares (or such owner’s predecessor in interest), and such Agreement is available for
inspection without charge at the office of the Secretary of the corporation.” 
 “The shares represented by this certificate have
not been registered under the Securities Act of 1933, as amended, and may not be sold, transferred or otherwise disposed of in the absence of an effective registration statement under such Act or an opinion of counsel satisfactory to the corporation
to the effect that such registration is not required.” 
  

	10.	 Provisions of the Plan. 

This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement. 

 

	11.	 Investment Representations. 

The Participant represents, warrants and covenants as follows: 

(a) The Participant is purchasing the Shares for Participant’s own account for investment only, and not with a view to, or for sale in
connection with, any distribution of the Shares in violation of the Securities Act, or any rule or regulation under the Securities Act. 

  
 6 

 (b) The Participant has had such opportunity as Participant has deemed adequate to obtain
from representatives of the Company such information as is necessary to permit him to evaluate the merits and risks of Participant’s investment in the Company. 

(c) The Participant has sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the
purchase of the Shares and to make an informed investment decision with respect to such purchase. 
 (d) The Participant can afford a
complete loss of the value of the Shares and is able to bear the economic risk of holding such Shares for an indefinite period. 
 (e) The
Participant understands that (i) the Shares have not been registered under the Securities Act and are “restricted securities” within the meaning of Rule 144 under the Securities Act; (ii) the Shares cannot be sold, transferred or
otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is then available; (iii) in any event, the exemption from registration under Rule 144 will not be available for at least
one year and even then will not be available unless a public market then exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and
(iv) there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act.

  

	12.	 Withholding Taxes; Section 83(b) Election. 

(a) The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant
any federal, state or local taxes of any kind required by law to be withheld with respect to the purchase of the Shares by the Participant or the lapse of the Purchase Option. 

(b) The Participant has reviewed with the Participant’s own tax advisors the federal, state, local and foreign tax consequences of this
investment and the transactions contemplated by this Agreement. The Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents. The Participant understands that the Participant
(and not the Company) shall be responsible for the Participant’s own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. The Participant understands that it may be beneficial in many
circumstances to elect to be taxed at the time the Shares are granted by the Company rather than when and as the Company’s Purchase Option expires by filing an election under Section 83(b) of the Internal Revenue Code of 1986 with the
I.R.S. within 30 days from the date of grant by the Company. 
 THE PARTICIPANT ACKNOWLEDGES THAT IT IS SOLELY THE PARTICIPANT’S
RESPONSIBILITY AND NOT THE COMPANY’S TO FILE TIMELY THE ELECTION UNDER SECTION 83(b), EVEN IF THE PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON THE PARTICIPANT’S BEHALF. 

  
 7 

	13.	 Miscellaneous. 

(a) No Rights to Employment. The Participant acknowledges and agrees that the vesting of the Shares pursuant to Section 3 hereof is
earned only by the Participant’s continuous Service (not through the act of being hired or purchasing the Shares hereunder). The Participant further acknowledges and agrees that the transactions contemplated hereunder and the vesting schedule
set forth herein do not constitute an express or implied promise of continued engagement as an employee or consultant for the vesting period, for any period, or at all. 

(b) Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability
of any other provision of this Agreement, and each other provision of this Agreement shall be severable and enforceable to the extent permitted by law. 

(c) Waiver. Any provision for the benefit of the Company contained in this Agreement may be waived, either generally or in any
particular instance, by the Board of Directors of the Company. 
 (d) Binding Effect. This Agreement shall be binding upon and inure
to the benefit of the Company and the Participant and their respective heirs, executors, administrators, legal representatives, successors and assigns, subject to the restrictions on transfer set forth in Sections 5 and 6 of this Agreement. 

(e) Notice. All notices required or permitted hereunder shall be in writing and deemed effectively given upon personal delivery or five
days after deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party hereto at the address shown beneath his or her or its respective signature to this Agreement, or at such other
address or addresses as either party shall designate to the other in accordance with this Section 13(e). 
 (f) Pronouns.
Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. 

(g) Entire Agreement. This Agreement and the Plan constitute the entire agreement between the parties, and supersedes all prior
agreements and understandings, relating to the subject matter of this Agreement. 
 (h) Amendment. This Agreement may be amended or
modified only by a written instrument executed by both the Company and the Participant. 
 (i) Governing Law. This Agreement shall be
construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflict of law principles. 

(j) Participant’s Acknowledgments. The Participant acknowledges that he or she: (i) has read this Agreement; (ii) has
been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of the Participant’s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this
Agreement; (iv) is fully 

  
 8 

 
aware of the legal and binding effect of this Agreement; and (v) understands that the law firm of WilmerHale is acting as counsel to the Company in connection with the transactions
contemplated by the Agreement, and is not acting as counsel for the Participant. 
 [Remainder of Page Intentionally Left Blank] 

  
 9 

 IN WITNESS WHEREOF, the parties hereto have executed the Restricted Stock Agreement as of
the date and year first above written. The Participant hereby agrees to the terms and conditions thereof. The Participant hereby acknowledges receipt of a copy of the Company’s 2016 Stock Incentive Plan. 

 

					
	COMPANY:
	
	Kyn Therapeutics Inc.
		
	By:	 	      

		 	Name:	 	  

		 	Title:	 	  

			
	Address:	 		 	6405 Williams Ridge Way Austin, TX 78731

  

					
	PARTICIPANT:
		
	By:	 	      

		 	[Name]	 	
			
	Address:	 		 	[                    ]
		 		 	[                    ]

  

					
	SPOUSAL CONSENT:
		
	By:	 	      

		 	Name:	 	
			
	Address:	 		 	[                    ]
		 		 	[                    ]

SIGNATURE PAGE TO RESTRICTED STOCK AGREEMENT 

GRANTED UNDER STOCK INCENTIVE PLANEX-10.7

 Exhibit 10.7 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND 

REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM 

THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE 

COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 

LICENSE AGREEMENT 

BY AND BETWEEN 

ARRYS THERAPEUTICS, INC. 

AND 

ASKAT, INC. 

 TABLE OF CONTENTS 

 

					
	 	  	PAGE	 
	 ARTICLE 1 DEFINITIONS
	  	 	1	 
	 ARTICLE 2 TECHNOLOGY TRANSFER
	  	 	12	 
	 ARTICLE 3 RESEARCH, DEVELOPMENT AND COMMERCIALIZATION
	  	 	13	 
	 ARTICLE 4 LICENSES, ASSIGNMENT AND EXCLUSIVITY
	  	 	15	 
	 ARTICLE 5 FINANCIALS
	  	 	16	 
	 ARTICLE 6 INTELLECTUAL PROPERTY
	  	 	21	 
	 ARTICLE 7 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	26	 
	 ARTICLE 8 INDEMNIFICATION
	  	 	32	 
	 ARTICLE 9 CONFIDENTIALITY
	  	 	34	 
	 ARTICLE 10 TERM AND TERMINATION
	  	 	37	 
	 ARTICLE 11 DISPUTE RESOLUTION
	  	 	39	 
	 ARTICLE 12 MISCELLANEOUS
	  	 	41	 

 LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of December 14, 2017 (the “Effective
Date”) by and among Arrys Therapeutics, Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at c/o OrbiMed Advisors, LLC, 601 Lexington Avenue, 54th Floor, New York, NY 10022 (“Arrys”) and AskAt Inc., a company organized under the laws of Japan and having its principal place of business at [***], Nagoya, Japan, 466-0841 (“AskAt”). Arrys and AskAt are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

BACKGROUND 
 AskAt owns or
otherwise controls certain materials, patents, patent applications, technology, know-how, scientific and technical information and other proprietary rights and information relating to EP4 Antagonists. 

AskAt owns certain patents and patent applications relating to methods of the treatment of cancer. 

Arrys is a newly formed company that was formed for the purpose of entering into this Agreement. 

AskAt has agreed to grant to Arrys an exclusive license under the Licensed Technology to Exploit the Licensed Compounds and Licensed Products
(all as defined below), and Arrys desires to receive such license, in accordance with the terms and conditions set forth herein. 
 NOW
THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS

 As used in this Agreement, the following initially capitalized terms, whether used in the singular or plural form, shall have the
meanings set forth in this Article 1. 
 1.1 “007 Composition Product” means any Composition Product containing
[***]. 007 Composition Products are “Composition Products”, as defined below. 
 1.2 “007 Composition Royalty-Bearing
Products” has the meaning set forth in Section 5.3(a). 
 1.3 “007 Development Milestone” means the
sooner of (a) Initiation of the first Phase II or Phase III Clinical Trial of an 007 Composition Product, whichever occurs first, provided however, that in no event shall Initiation of any Phase I Clinical Trial (including any phase 1b clinical
trial) described in the Development Plan as of the Effective Date be grounds for achievement of the 007 Development Milestone or (b) the [***] following the formal adoption of a binding resolution by the Board of Directors of Arrys authorizing
the Initiation of a Phase II or Phase III Clinical Trial that if Initiated would satisfy clause (a) of this definition. 
 1.4
“007 Development Milestone Fee” has the meaning set forth in Section 5.2(a). 

 1.5 “007 Patents” means any and all Composition Patents other than the 008
Patents. 
 1.6 “007 Technology” means all Composition Technology other than the 008 Technology. 

1.7 “008 Composition Product” means any product containing [***]. 008 Composition Products are “Composition
Products”. 
 1.8 “008 Composition Royalty-Bearing Products” has the meaning set forth in Section 5.3(a).

 1.9 “008 Development Milestone” means the sooner of (a) Initiation of the first Phase II or Phase III Clinical
Trial of an 008 Composition Product, whichever occurs first, provided however, that in no event shall Initiation of any Phase I Clinical Trial (including any phase 1b clinical trial) described in the Development Plan as of the Effective Date be
grounds for achievement of the 008 Development Milestone or (b) the [***] following the formal adoption of a binding resolution by the Board of Directors of Arrys authorizing the Initiation of a Phase II or Phase III Clinical Trial that
if Initiated would satisfy clause (a) of this definition. 
 1.10 “008 Development Milestone Fee” has the
meaning set forth in Section 5.2(b). 
 1.11 “008 Patents” means any and all Composition Patents that are
solely related to, claim or cover [***]. 
 1.12 “008 Technology” means the (a) Composition Know-How that solely describes or contains Know-How related to [***]. 

1.13 “505(b)(2) NDA” means a new drug application submitted to the FDA under 21 U.S.C. § 355(b)(2) (or any
replacement thereof). 
 1.14 “AAA” has the meaning set forth in Section 11.3. 

1.15 “AAT-007” means [***]. 

1.16 “AAT-008” means [***]. 

1.17 “Affiliate” means, with respect to a particular Person, a person, corporation, partnership, or other entity that
controls, is controlled by or is under common control with such Person. For the purposes of this definition, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control
with”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than [***] of the voting stock of
such entity, or by contract or otherwise. For the avoidance of doubt, Kyn Therapeutics and Arrys are not Affiliates of each other for purposes of this Agreement. 

1.18 “Agreement” has the meaning set forth in the preamble hereto. 

1.19 “ANDA” means an Abbreviated New Drug Application pursuant to 21 U.S.C. § 355(j) and 21 C.F.R. §
314.3. 

  
 2 

 1.20 “Applicable Law” means the applicable laws, rules, regulations,
guidelines and other requirements of Governmental Authorities, including Regulatory Authorities, that may be in effect from time to time, including GLP, GMP, the UK Bribery Act of 2010 and the Foreign Corrupt Practices Act of 1977, as amended. 

1.21 “Arrys Indemnitees” has the meaning set forth in Section 8.1. 

1.22 “Arrys Sublicensee” means any Third Party granted a sublicense by Arrys, any of its Affiliates or any other Arrys
Sublicensee under the rights granted to Arrys hereunder (such sublicense, a “Arrys Sublicense”). 
 1.23 “AskAt
Indemnitees” has the meaning set forth in Section 8.2. 
 1.24 “AskAt Outbound Agreements” means,
collectively, the following: [***]. 
 1.25 “[***] Agreements” means, collectively, the following: [***]. 

1.26 “Bankruptcy Code” has the meaning set forth in Section 10.3(b). 

1.27 “Business Day” means a day other than a Saturday or a Sunday or a bank or other public holiday in Tokyo, Japan or New
York, New York, for AskAt or Arrys, respectively. 
 1.28 “Calendar Quarter” means the respective periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 
 1.29
“Calendar Year” means each successive period of twelve (12) months commencing on January 1 and ending on December 31. 

1.30 “Change of Control” means, with respect to a Person, (a) completion of a merger, reorganization, amalgamation,
arrangement, share exchange, consolidation, tender or exchange offer, private purchase, business combination, recapitalization or other transaction as a result of which the stockholders of the Person immediately preceding such transaction hold less
than [***] of the outstanding shares, or less than [***] of the outstanding voting power, respectively, of the ultimate company or entity resulting from such transaction immediately after consummation thereof (including a company or entity which as
a result of such transaction owns the then-outstanding securities of the Person or all or substantially all of such Person’s assets, either directly or through one or more subsidiaries), (b) the adoption of a plan relating to the liquidation or
dissolution of the Person, other than in connection with a corporate reorganization (without limitation of clause (a), above), (c) any sale, lease, exchange, exclusive license, contribution or other transfer (in one transaction or a series of
related transactions) to a Third Party of all or substantially all the assets of the Person (determined on a consolidated basis), or (d) the sale or disposition to a Third Party of assets or businesses that constitute [***] or more of the total
revenue or assets of the Person (determined on a consolidated basis). 
 1.31 “Claim” has the meaning set forth in
Section 8.3. 
 1.32 “Clinical Trials” means Phase I Clinical Trials, Phase II Clinical Trials,
Phase III Clinical Trials, Phase IV Clinical Trials or Pivotal Trials. 

  
 3 

 1.33 “Combination Product” means a Licensed Product that, in addition to
containing a Licensed Compound as an active ingredient, also contains at least one other active pharmaceutical ingredient that is not a Licensed Compound. 

1.34 “Commercialize” or “Commercialization” means, together with all correlative meanings, the import,
export, marketing, promotion, sale or distribution of a product, including commercial activities conducted in preparation for a product launch. Commercialization shall expressly exclude (a) Research, (b) Development and (c) Manufacture.

 1.35 “Commercially Reasonable Efforts” means, with respect to a Party’s obligations that relate to the achievement
of an objective, the use of reasonable, diligent efforts and resources (including use and expenditure of resources) as normally used by similarly situated companies in the relevant field for the achievement of the same or a similar objective on a
timely basis for such company’s similarly situated therapeutic products at a similar stage of development and with similar commercial potential, taking into account all relevant factors, including safety and efficacy, product profile, the
proprietary position, the then-current competitive environment and the likely timing of market entry, the regulatory environment and status, and other relevant scientific, technical and commercial factors, all as determined at the time such
obligations are due. 
 1.36 “Compartment Specific Product” means any product containing a Licensed Compound that is
administered to a restricted tissue or compartment of the human body for the purpose of local administration. For the avoidance of doubt the following are not Compartment Specific Products: (a) a product that is administered for the purpose of
systemic exposure by any means or (b) any product that is administered intravenously, by intra-muscular injection or by subcutaneous injection. 

1.37 “Composition Know-How” means any Know-How Controlled by AskAt or any of its
Affiliates on the Effective Date or during the Term that is necessary or useful to Exploit, or otherwise relates to, any Licensed Compound, 007 Composition Product or 008 Composition Product. 

1.38 “Composition Know-How Materials” means materials and information in any form
that describe or contain the Composition Know-How, including without limitation the Regulatory Materials that were available to Arrys pursuant to the Data Room immediately prior to the Effective Date. 

1.39 “Composition Patents” means any and all Patents Controlled by AskAt or any of its Affiliates on the Effective Date or
during the Term that are related to, claim or cover any Licensed Compound or Composition Product. 
 1.40 “Composition
Products” means any product containing a Licensed Compound. 
 1.41 “Composition Technology” means the Composition
Know-How and Composition Patents. 
 1.42 “Confidential Information” has the
meaning set forth in Section 9.1. 
 1.43 “Control” or “Controlled” means, with respect to any
data, information, materials, compounds, Know-How, Patents, Regulatory Materials or Regulatory Approvals, the possession (whether by ownership or license or other legal authority, but other than pursuant to

  
 4 

 
this Agreement) by a Party or its Affiliates of the ability to grant to the other Party a license or access as provided herein to such item, or to otherwise disclose proprietary or trade secret
information to such other Party without violating the terms of any agreement or other arrangement with any Third Party, in existence as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such license
or access. 
 1.44 “CPA Firm” has the meaning set forth in Section 5.4(d)(ii). 

1.45 “Data Room” means that certain information sharing electronic storage that contained AskAt’s Confidential
Information regarding AAT-007 and AAT-008 which Arrys evaluated and/or used to make the decision to enter into this License Agreement. 

1.46 “Develop” or “Development” means, together with all correlative meanings, pre-clinical and clinical drug development activities, conducted before or after obtaining Regulatory Approval that are reasonably related to or leading to the development, preparation, and submission of data and
information to a Regulatory Authority for the purpose of obtaining, supporting or expanding Regulatory Approval or to the appropriate body for obtaining, supporting or expanding pricing and reimbursement approval, including without limitation, all
activities related to preclinical testing, assay development and validation, in vivo testing, biomarker development and validation, toxicology, pharmacokinetic profiling, design and conduct of Clinical Trials and any other clinical trials or
studies, regulatory affairs, statistical analysis, report writing, and Regulatory Material creation and submission (including the services of outside advisors and consultants in connection therewith). Development expressly excludes (a) Research, (b)
Commercialization and (c) the Manufacture and accumulation of commercial inventory of a product. 
 1.47 “Development Plan”
means the development plan with respect to AAT-007 and AAT-008 set forth on Exhibit B, as it may be reasonably amended or modified by Arrys from time to time. For the avoidance of doubt, any terms of
this Agreement, including but not limited to the definition of “007 Development Milestone” and “008 Development Milestone”, may not be amended or modified by the Development Plan. 

1.48 “Disputes” shall have the meaning set forth in Section 11.1. 

1.49 “Drug Substance” means the bulk drug substance manufactured by or on behalf of AskAt that contains a Licensed Compound.

 1.50 “Effective Date” has the meaning set forth in the preamble to this Agreement. 

1.51 “EP4 Antagonist” means any small molecule that blocks the EP4 receptor. 

1.52 “EMA” means the European Medicines Agency or its successor. 

1.53 “EU” means all of the European Union member states as of the applicable time during the Term. 

1.54 “Exploit” or “Exploitation” means, collectively, to make, have made, use, have used, sell, have sold,
offer for sale, have offered for sale, import, have imported, export, have exported and otherwise exploit and have exploited, including Research, Develop, Manufacture and Commercialize. 

  
 5 

 1.55 “FDA” means the United States Food and Drug Administration or its
successor. 
 1.56 “FD&C Act” means the United States Federal Food, Drug and Cosmetic Act, as amended. 

1.57 “Field” means the treatment, prevention, diagnosis or prognosis of diseases or disorders in humans, other than by means
of administration of a Compartment Specific Product; provided that AAT-007 human injectable use is included in the Field only with respect to the treatment, prevention, diagnosis or prognosis of cancer using an injectable formulation thereof, and
further provided that if AskAt obtains any additional rights to an injectable formulation of AAT-007 other than a Compartment Specific Product with respect to the treatment, prevention, diagnosis or prognosis of diseases or disorders in humans, the
“Field” shall automatically be expanded, without further action of either Party, to include all such rights. 
 1.58
“First Commercial Sale” means, with respect to a Licensed Product and a country, the first sale to a Third Party of such Licensed Product in such country after all Regulatory Approvals, including any pricing or reimbursement
approvals, as applicable, have been obtained in such country. 
 1.59 “Generic Product” means, with respect to a Licensed
Product in a country, a pharmaceutical product that: (a) (i) contains the same active moiety as the Licensed Product; and (ii) is approved for use or marketing in such country by a Regulatory Authority through an ANDA or 505(b)(2) NDA, or any
enabling legislation thereof, or pursuant to any similar abbreviated route of approval in any countries in the Territory; or (b) (i) contains the same active moiety as the Licensed Product; and (ii) is approved for use in such country by a
Regulatory Authority through a regulatory pathway referencing or relying on clinical data, or any findings of safety or efficacy therein, first submitted by Arrys or its Affiliates or Arrys Sublicensees for obtaining Regulatory Approval for such
Licensed Product, in each case other than any Licensed Product that has been Developed under this Agreement by or on behalf of Arrys or any of its Affiliates or Arrys Sublicensees or Commercialized by or on behalf of Arrys or any of its Affiliates
or Arrys Sublicensees in such country. As used herein, the term “active moiety” has the meaning set forth in Title 21, United States Code of Federal Regulations, § 314.108(a). 

1.60 “Good Laboratory Practices” or “GLP” means the then-current practices and procedures set forth in Title
21, United States Code of Federal Regulations, Part 58 (as amended), and any other regulations, guidelines or guidance documents relating to good laboratory practices, or any foreign equivalents thereof in the country in which such studies or
clinical trials are conducted. 
 1.61 “Good Manufacturing Practices” or “GMP” means the then-current
practices and procedures set forth in Title 21, United States Code of Federal Regulations, Parts 210 – 211, ICH Guideline Q7A, and any other regulations, guidelines or guidance documents relating to good manufacturing practices, or any foreign
equivalents thereof in the country in which such manufacturing activities are conducted. 
 1.62 “Governmental Authority”
means any multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). 

  
 6 

 1.63 “IND” means (a) an Investigational New Drug Application as defined in
the FD&C Act and applicable regulations promulgated thereunder by the FDA, or (b) a clinical trial application or similar equivalent application or submission to the equivalent Regulatory Authority in any other regulatory jurisdiction, the
filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction. 
 1.64
“Indemnified Party” has the meaning set forth in Section 8.3. 
 1.65 “Indemnifying Party” has the
meaning set forth in Section 8.3. 
 1.66 “Infringement Notice” has the meaning set forth in Section
6.4(a). 
 1.67 “Initiation” or “Initiate” means, together with all correlative meanings, the first
dosing of the first subject or patient in a Clinical Trial of a Licensed Product to be conducted by or on behalf of Arrys or any of its Affiliates. 

1.68 “Initiation Fee” has the meaning set forth in Section 5.1. 

1.69 “Inventions” mean all inventions, discoveries, improvements, modifications, enhancements or creations, in each case
whether or not patentable and whether or not reduced to practice, and any intellectual property rights (including Know-How and Patents) arising from any of the foregoing. 

1.70 “Joint Invention” means any Invention developed, created, conceived or reduced to practice jointly by or on behalf of
the Parties in connection with and during the Term of this Agreement. For the purposes of clarity, Joint Inventions includes Inventions developed by Arrys that incorporate Licensed Know-How. 

1.71 “Joint Patent” means any Patent that is related to, claims or covers any Joint Invention. 

1.72 “Know-How” means any data, results, and information of any type whatsoever, in any tangible or intangible form,
including know-how, inventions, discoveries, developments, trade secrets, practices, techniques, methods, processes, specifications, formulations, formulae, materials or compositions of matter of any type or kind (patentable or otherwise), software,
algorithms, marketing reports, clinical and non-clinical study reports, regulatory submission documents and summaries, technology, test data including pharmacological, biological, chemical, biochemical, toxicological, and clinical test data,
analytical and quality control data, stability data, studies and procedures. 
 1.73
“Know-How Materials” means the Composition Know-How Materials and Treatment Know-How Materials. 

1.74 “Licensed Compound” means each of [***]. 

1.75 “Licensed Know-How” means the Composition Know-How and the Treatment Know-How. 

1.76 “Licensed Patents” means the Composition Patents and the Treatment Patents. The Licensed Patents Controlled by AskAt or
any of its Affiliates on the Effective Date are set forth on Exhibit A. For the avoidance of doubt, Licensed Patents includes AskAt’s interest in any Joint Patents. 

  
 7 

 1.77 “Licensed Products” with respect to the Composition Technology, means
the Composition Products, and with respect to the Treatment Technology, means the Treatment Products, in each case, other than Compartment Specific Products. 

1.78 “Licensed Technology” means the Composition Technology and the Treatment Technology. 

1.79 “Manufacture” means, with respect to a product, those manufacturing activities involved in or relating to
(a) manufacturing process development, (b) CMC activities including analytical development and qualification, formulation development, solubility testing, bulk drug substance manufacturing, stability testing and scale-up activities, bulk drug product manufacturing and stability testing, (c) quality assurance and quality control activities including validation testing, qualification and audit of clinical and commercial
manufacturing facilities, and (d) in the case of either a clinical or commercial supply of such product or supply of such product for any non-clinical study, the manufacturing, processing, formulating,
packaging, labeling, holding, quality control testing and release of such product. 
 1.80 “Marketing Authorization
Application” or “MAA” means an application for Regulatory Approval in a country, territory or possession. 
 1.81
“NDA” means a New Drug Application, as defined in the FD&C Act and applicable regulations promulgated thereunder by the FDA, or any analogous application or submission with any Regulatory Authority outside of the United States.

 1.82 “Net Sales” means the gross amount invoiced by Arrys and its Affiliates and Arrys Sublicensees for sales or other
transfers of each Royalty-Bearing Product to a Third Party less the following: 
 (i) customary trade, quantity, or cash
discounts, credits or allowances to the extent actually allowed and taken; 
 (ii) rebates and allowances, including
chargebacks and retroactive price reductions, hospital buying group/group purchasing organization administration fees or managed care organization rebates actually given; 

(iii) rebates and similar payments made with respect to sales paid for by any governmental or regulatory authority such as
Federal or state Medicaid, Medicare or similar state program; 
 (iv) amounts repaid or credited by reason of defects,
recalls, rejections or returns; 
 (v) to the extent separately stated on purchase orders, invoices, or other documents of
sale, any taxes or other governmental charges levied on the production, sale, transportation, delivery or use of a Royalty-Bearing Product which is paid by or on behalf of Arrys; and 

  
 8 

 (vi) to the extent separately stated on purchase orders, invoices, or other
documents of sale, outbound transportation costs prepaid or allowed and costs of insurance in transit. 
 For the avoidance of doubt, the following shall
not be considered Net Sales hereunder: (A) transfers of a Royalty-Bearing Product between any of Arrys, its Affiliates or Arrys Sublicensees for sale by the transferee, (B) transfers of samples of a Royalty-Bearing Product used to promote
additional Net Sales, and (C) disposal or use of Royalty-Bearing Product in Clinical Studies or under compassionate use, patient assistance, named patient use, or test marketing programs or
non-registrational studies or other similar programs or studies. 
 In the event that a Royalty-Bearing Product is
sold as a Combination Product, Net Sales, for the purposes of determining royalty payments on the Combination Product, shall mean the gross amount collected for the Combination Product less the deductions set forth in clauses above, multiplied
by a proration factor that is determined as follows on a country-by-country basis: 

(1) If all components of the Combination Product were sold separately during the same or immediately preceding Reporting
Period in a single country, the proration factor shall be determined by the formula [a /(a+b)], where a is the average gross sales price of all Royalty-Bearing Product components (as applicable) during such period when sold separately from the
other component(s) in such country, and b is the average gross sales price of the other component(s) during such period when sold separately from the Royalty-Bearing Product components (as applicable) in such country; or 

(2) If all components of the Combination Product were not sold or provided separately during the same or immediately preceding
Reporting Period in a single country, the proration factor shall be determined by the Parties in good faith negotiations based on the relative value contributed by each component. 

1.83 “Net Sales Royalty” has the meaning set forth in Section 5.4(a). 

1.84 “Net Sales Statement” has the meaning set forth in Section 5.4(a). 

1.85 “Party” or “Parties” has the meaning set forth in the preamble to this Agreement. 

1.86 “Patent” means (a) any national or regional patent or national, regional or international patent application,
anywhere in the world, including any provisional patent application, (b) any patent application filed either claiming priority to such a patent, patent application or provisional application or from an application claiming priority to any of
these, including any divisional, continuation, continuation-in-part, (c) any patent that has issued or in the future issues from any of the foregoing patent
applications (in each case (a) and (b)), including any utility model, petty patent, design patent and certificate of invention, (d) any extension or restoration by existing or future extension or restoration mechanisms, including any
revalidation, reissue, re-examination and extension (including any supplementary protection certificate and the like in any jurisdiction) of any of the foregoing patents or patent applications (in each case
(a), (b) and (c)), and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions
to any such foregoing patent application or patent. 

  
 9 

 1.87 “Person” means an individual, sole proprietorship, partnership,
limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or
political subdivision, department or agency of a government. 
 1.88 “Phase I Clinical Trial(s)” means a human clinical
trial(s) of a product, the principal purpose of which is a determination of initial tolerance or safety of such product in healthy volunteers and/or the target patient population, as described in 21 CFR 312.21(a) (as amended or any replacement
thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States. 
 1.89
“Phase II Clinical Trial” means a human clinical trial of a product, the principal purpose of which is a determination of safety and efficacy in the target patient population, as described in 21 C.F.R. 312.21(b) (as amended or any
replacement thereof), or a similar clinical trial prescribed by the Regulatory Authority in a country other than the United States. 
 1.90
“Phase III Clinical Trial” means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any
replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to
satisfy the requirements of a pivotal efficacy and safety clinical trial. 
 1.91 “Phase IV Clinical Trial” means any study
of a product following the first Regulatory Approval for the sale of such product whether or not required by a Governmental Authority. Phase IV Clinical Trials may include epidemiological studies, modeling and pharmacoeconomic studies,
post-marketing surveillance studies and clinical or other research studies. 
 1.92 “Pivotal Trial” means, with respect to
any Licensed Product, a Clinical Trial that at the time of commencement (or any later expansion of patient enrollment, if applicable), is expected by Arrys to be the basis for Regulatory Approval with respect to Clinical Trials for such Licensed
Product. 
 1.93 “[***]” means [***]. 

1.94 “[***] License Agreements” means, collectively, the following: [***]. 

1.95 “Regulatory Approval” means all approvals necessary for the Manufacture, marketing, importation and sale of a product
for one or more indications in a country or regulatory jurisdiction, which may include satisfaction of all applicable regulatory and notification requirements, including any pricing and reimbursement approvals. Regulatory Approvals include approvals
by Regulatory Authorities of INDs, MAAs, or NDAs. 
 1.96 “Regulatory Authority” means, in a particular country or
regulatory jurisdiction, any applicable Governmental Authority involved in granting Regulatory Approval or, to the extent required in such country or regulatory jurisdiction, pricing or reimbursement approval of a product in such country or
regulatory jurisdiction, including (a) the FDA, (b) the EMA, and (c) the European Commission, or its successor. 

  
 10 

 1.97 “Regulatory Materials” means regulatory applications, submissions,
notifications, registrations, or other filings made to or with a Regulatory Authority that are necessary or reasonably desirable in order to Develop, Manufacture, market, sell or otherwise Commercialize a Licensed Compound or a Composition Product
in any country or regulatory jurisdiction within the Territory. Regulatory Materials include INDs, MAAs and NDAs (as applications, but not the approvals with respect thereto). Regulatory Materials shall include, without limitation, those materials
and information described on Schedule 1.97. 
 1.98 “Related Know-How and
Inventions” shall have the meaning set forth in Section 10.5(a)(iv). 
 1.99 “Research” means,
together with all correlative meanings, activities related to the discovery, identification, profiling, characterization, advancement or progression of compounds. Research shall expressly exclude (a) Development, (b) Commercialization and
(c) Manufacture. 
 1.100 “Retention Field” means all fields except for the Field. 

1.101 “Royalty-Bearing Products” means any Licensed Product, the manufacture, use, sale or administration of which is claimed
or covered by any of the Licensed Patents or that utilizes or incorporates any of the Licensed Know-How. 

1.102 “Royalty Rate” has the meaning set forth in Section 5.4(a). 

1.103 “Royalty Term” means, on a
country-by-country and Royalty-Bearing Product-by-Royalty-Bearing Product basis, the
period beginning with the First Commercial Sale of such product in such country and ending (a) [***] from the date of the First Commercial Sale of such Royalty-Bearing Product in such country, or (b) the expiration date in such country of the
last to expire Valid Claim within the (i) Composition Patents claiming or covering the composition of matter of such Royalty-Bearing Product in such country or (ii) Treatment Patents that claim or cover the manufacture, use or sale of such
Royalty-Bearing Product, whichever of (a) or (b) is longer. 
 1.104 “SEC” means the U.S. Securities and Exchange
Commission. 
 1.105 “Term” has the meaning set forth in Section 10.1. 

1.106 “Territory” means worldwide other than China and Taiwan. 

1.107 “Third Party” means any Person other than Arrys or AskAt or their respective Affiliates. 

1.108 “Treatment Know-How” means any Know-How
Controlled by AskAt or any of its Affiliates on the Effective Date or during the Term that is reasonably necessary or useful to Exploit, or otherwise relates to, the method of treatment claimed in the Treatment Patents. 

  
 11 

 1.109 “Treatment Know-How
Materials” means materials and information in any form that describe or contain the Treatment Know-How, including without limitation the materials that were available to Arrys pursuant to the Data
Room immediately prior to the Effective Date. 
 1.110 “Treatment Patents” means any and all Patents Controlled by AskAt or
any of its Affiliates on the Effective Date or during the Term that are related to, claim or cover any method of treating cancer. 
 1.111
“Treatment Product” means any product containing a Licensed Compound, Composition Product or any other compound, product, composition of matter or material, or any service, in each case, the manufacture, use, sale or administration
of which is claimed or covered by any of the Treatment Patents or that utilizes or incorporates any of the Treatment Know-How. 

1.112 “Treatment Technology” means the Treatment Know-How and Treatment Patents. 

1.113 “U.S.” means the United States of America and its possessions and territories. 

1.114 “Valid Claim” means a claim of any issued, unexpired United States or granted foreign Patent that has not been
dedicated to the public, disclaimed, irrevocably abandoned or held permanently invalid or unenforceable by a court or other body of competent jurisdiction from which no further appeal can be taken, and that has not been explicitly disclaimed, or of
a scope not covering a particular product or service through reissue, disclaimer or otherwise. 
 ARTICLE 2 

TECHNOLOGY TRANSFER 
 During the [***]
period immediately after the Effective Date, and periodically thereafter at Arrys’s reasonable request, AskAt shall, and shall cause its Affiliates and contractors to, reasonably cooperate with Arrys to facilitate the technology transfer of
Licensed Technology, Licensed Compounds and Licensed Products to enable the Research, Development, Manufacture and Commercialization of Licensed Compounds and Licensed Products, in each case, by providing the relevant information and materials then
in the possession of AskAt or any of its Affiliates or contractors. Furthermore, such technology transfer may include providing Arrys, and any designated contract manufacturer of Arrys, with such assistance as may be necessary or useful to transfer
and implement the processes, methods and techniques used by or on behalf of AskAt in the Manufacture of Licensed Compounds or Licensed Products as of the Effective Date. In addition to the foregoing, such cooperation shall include providing Arrys
with reasonable access by teleconference or in-person at AskAt’s and AskAt’s Affiliates’, and its and their contractors’, facilities to appropriate personnel from AskAt and its Affiliates, and its and their contractors, to
provide Arrys with a reasonable level of technical assistance and consultation in connection with the transfer of Licensed Technology, Licensed Compounds and Licensed Products. Arrys shall reimburse AskAt for its reasonable and reasonably documented
out-of-pocket costs incurred in connection with providing such assistance under this Article 2, but in no event shall Arrys pay for any such expenses hereunder if Arrys is obligated to pay any of the same expenses pursuant to that
certain Consulting and Supply Agreement, by and between the Parties, dated on or about the date hereof. 

  
 12 

 ARTICLE 3 

RESEARCH, DEVELOPMENT AND COMMERCIALIZATION 

3.1 Research and Development. As of the Effective Date, Arrys shall have sole responsibility for and sole decision-making (subject to
the limitations on amendments and modifications set forth in the Development Plan) over the Research and Development of all Licensed Compounds and Licensed Products in the Field and Territory, and associated costs and expenses. 

3.2 Regulatory Responsibilities. As of the Effective Date, Arrys shall have sole responsibility for and sole decision-making over all
regulatory activities and associated costs and expenses for the Licensed Compounds and Licensed Products in the Territory, both before and after obtaining Regulatory Approval. Without limiting the foregoing, (a) Arrys shall have sole control
over preparing and submitting all Regulatory Materials related to the Licensed Compounds and Licensed Products, including all INDs and all applications for Regulatory Approval; (b) Arrys shall own any and all applications for Regulatory
Approvals, the Regulatory Approvals, and other Regulatory Materials related to the Licensed Compounds and Licensed Products, which shall be held in the name of Arrys or its designees; (c) the decision whether to file an IND for any particular
Licensed Compound or Licensed Product and the contents of such IND shall be at Arrys’s sole discretion; (d) Arrys shall have the sole right to conduct all communications with Regulatory Authorities, including all meetings, conferences and
discussions (including advisory committee meetings), with regard to Licensed Compounds and Licensed Products in the Territory; provided that, if Arrys requests that AskAt or its Affiliates interact with a Regulatory Authority, the Parties
shall discuss such request in good faith, and if the Parties agree, AskAt shall, at Arrys’s cost, engage, or shall cause its Affiliates to engage, as applicable, in such interaction with such Regulatory Authority. Arrys shall reimburse AskAt
for its reasonable and reasonably documented out-of-pocket costs incurred in connection with providing such assistance within [***] of receipt of an invoice from AskAt.

 3.3 Manufacturing. Promptly following the Effective Date, upon request from Arrys, AskAt shall, and shall cause its Affiliates to,
use Commercially Reasonable Efforts to assign to Arrys or its designee all then-existing Manufacturing contracts with Third Party contract manufacturers, if any, that are related to the Manufacture of any of the Licensed Compounds or Composition
Products. As of the Effective Date, Arrys shall have sole responsibility for and sole decision-making authority over all Manufacturing activities and associated costs and expenses for the Manufacturing of the Licensed Compounds and Composition
Products in the Field. Without limiting the foregoing, at Arrys’s request, the Parties shall negotiate in good faith the terms of a manufacturing and supply agreement to be entered into by them for purposes of AskAt’s supplying Drug
Substance to Arrys or any of its Affiliates or Arrys Sublicensees. 
 3.4 Commercialization. As of the Effective Date, Arrys shall
have sole responsibility for and sole decision-making over all Commercialization activities of the Licensed Products in the Field, including choosing the brand(s) under which the Licensed Products shall be Commercialized. After the Effective Date,
Arrys shall be solely responsible for the associated costs and expenses of such Commercialization activities. 

  
 13 

 3.5 Diligence. Arrys shall use Commercially Reasonable Efforts to Develop and
Commercialize at least one Licensed Product, including but not limited to, (a) completing a Phase I Clinical Trial of an 008 Composition Product and (b) Exploiting at least [***] Licensed Product in the Field in the Territory, in each
case, in accordance with the Development Plan. For the avoidance of doubt, the following shall be a breach of Arrys’s obligation under this Section 3.5: Arrys and all of its Affiliates and each Arrys Sublicensee ceases all
Development of all Licensed Products and Licensed Compounds for [***]. 
 3.6 Reports. Regarding the Arrys’s report to AskAt,
Arrys agrees as follows: 
 (a) Within [***] following the end of each June and December, Arrys shall provide to AskAt a report summarizing
in general terms the Development, Commercialization, and Manufacture of Licensed Products hereunder until (i) the First Commercial Sale of the first Licensed Product or (ii) Arrys, its Affiliates and Arrys’s Sublicensees cease all
Development of Licensed Products, whichever comes later. Each such report shall include a list of all Arrys’s Affiliates who are exercising rights under this Agreement and Arrys Sublicensees, and Government Approvals of Licensed Product
received. 
 (b) Within [***] following the First Commercial Sale of any Licensed Product, provide AskAt with written notice thereof,
including the name of the country in which such First Commercial Sale occurred. 
 (c) If this Agreement is terminated for any reason during
the Royalty Term, Arrys shall deliver a final report and associated royalty payment to AskAt in accordance with the terms hereof. 
 (d) (i)
Arrys shall promptly provide AskAt with copies of all safety data Controlled by Arrys or any of its Affiliates or any Arrys Sublicensee that satisfies each of the following requirements: (A) relates to any Licensed Compound or Licensed Product
and (B) could reasonably be expected to affect development of Compartment Specific Products. AskAt may use such data solely for developing, and having Third Parties develop for AskAt’s benefit, Compartment Specific Products. Without
limiting the foregoing, in no event may AskAt allow such data to be Exploited in the Field regardless of whether inside or outside the Territory. (ii) Notwithstanding anything herein to the contrary, following a written request from AskAt,
Arrys shall promptly provide AskAt with a copy of all such safety data that relates to any Licensed Compound or Licensed Product and that is required by a Governmental Authority, and AskAt may disclose such safety data to such Governmental Authority
if AskAt is required to do so by any Applicable Law or Governmental Authority; provided that AskAt shall request confidential treatment of such data to the extent allowed under Applicable Law. 

All information provided by Arrys pursuant to this Section 3.6 is the Confidential Information of Arrys. 

3.7 Change of Control of Arrys. The following changes shall automatically be made to this Agreement, effective simultaneously with the
effectiveness of a Change of Control of Arrys, without any action of either Party: 
 (a) Section 3.6(a) shall be deleted and
replaced with the following: “Within [***] following the end of each December, Arrys shall provide to AskAt a report summarizing in general terms the Development, Commercialization, and Manufacture of Licensed Products hereunder until
(i) the First Commercial Sale of the first Licensed Product or (ii) Arrys, its Affiliates and Arrys’s Sublicensees cease all Development of Licensed Products, whichever comes later. Each such report shall include a list of all Arrys
Sublicensees and Government Approvals of Licensed Product received.” 

  
 14 

 (b) Section 3.6(d) shall be deleted and replaced with the following:
“Notwithstanding anything herein to the contrary, Arrys shall promptly provide AskAt with a copy of safety data Controlled by Arrys or any of its Affiliates or any Arrys Sublicensee that satisfies each of the following requirements:
(i) relates to any Licensed Compound or Licensed Product, (ii) could reasonably be expected to affect development of Compartment Specific Products and (iii) is required by a Governmental Authority. AskAt may disclose such safety data
to such Governmental Authority if AskAt is required to do so by any Applicable Law or Governmental Authority; provided that AskAt shall request confidential treatment of such data to the extent allowed under Applicable Law.” 

(c) The last sentence of Section 5.4(d)(v) shall be deleted and replaced with the following: “If the report of the CPA Firm
shows that Arrys underpaid and if such discrepancy exceeds the greater of [***] of the amount audited or [***], then the reasonable fees and expenses of the CPA Firm in performing such audit shall be paid by Arrys”; and 

Arrys shall give AskAt written notice of negotiations with a Third Party that Arrys reasonably expects will result in a Change of Control of Arrys. Further,
Arrys shall give AskAt written notice within [***] of the consummation of a Change of Control of Arrys. 
 ARTICLE 4 

LICENSES, ASSIGNMENT AND EXCLUSIVITY 

4.1 Exclusive Licenses to Arrys. 

(a) Subject to the terms and conditions of this Agreement, AskAt hereby grants, on behalf of AskAt and its Affiliates, to Arrys and its
Affiliates an exclusive (even as to AskAt and its Affiliates but subject to Section 4.1(c)), transferable (as permitted in accordance with Section 12.6), license, with the right to sublicense (through multiple tiers), under
the Licensed Technology, to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory. Arrys shall be responsible to AskAt for all acts and omissions of each Arrys Affiliate that exercises rights under this Agreement as if
each such act and omission were an act or omission, as applicable, of Arrys. 
 (b) Each Arrys Sublicensee shall enter into a written
agreement with Arrys, one of its Affiliates or the relevant Arrys Sublicensee that is consistent with the relevant terms and conditions of this Agreement. Within [***] after the execution of an agreement that is a Arrys Sublicense, Arrys shall
deliver to AskAt a complete and accurate copy of the entire such agreement written in English language. AskAt’s receipt of such agreement, however, will constitute neither an approval of such sublicense nor a waiver of any right of AskAt or
obligation of Arrys under this Agreement. As between the Parties, Arrys is primarily liable to AskAt for any act or omission of its Affiliate or Arrys’s Sublicensees that would be a breach of this Agreement if performed or omitted by Arrys.

  
 15 

 (c) AskAt reserves the right to Exploit the Licensed Compound or Licensed Product
(i) in the Retention Field worldwide or (ii) outside the Territory. For clarity, the license granted in Section 4.1(a) does not include, expressly or by implication, a license under License Technology to Exploit any Licensed
Compound or Licensed Product in the Retention Field or outside the Territory, therefore, in no event will Arrys Exploit the Licensed Compounds and Licensed Product as Compartment Specific Product in the Territory or any product outside the
Territory. 
 (d) Subject to this Agreement, to the extent any Know-How Materials are subject to
copyright, or are copyrightable, anywhere in the Territory, AskAt hereby grants, on behalf of AskAt and its Affiliates, to Arrys and its Affiliates an exclusive (even as to AskAt and its Affiliates), transferable (as permitted in accordance with
Section 12.6), license, with the right to sublicense (through multiple tiers), under the Know-How Materials, to reproduce, display, distribute, modify and create derivative works and/or perform the
works of authorship that are the subject matter of the Know-How Materials in connection with the Exploitation of the Licensed Compounds and Licensed Products in the Field in the Territory. 

(e) In the event that any rights in the Field in the Territory revert to AskAt pursuant to the termination, expiration, amendment, amendment
and restatement or other event or action with respect to any [***] Agreement, AskAt Outbound Agreement or [***] License Agreement, such rights shall automatically be included in the license grants set forth in Section 4.1(a) and
Section 4.1(c) without any further action by a Party. 
 4.2 No Implied Licenses. Except as explicitly set forth in this
Agreement, neither Party grants to the other Party any license or other rights, express or implied, under any intellectual property rights (whether by implication, estoppel or otherwise). 

4.3 Assignment of Regulatory Materials. Subject to the terms and conditions of this Agreement, AskAt hereby assigns to Arrys, on behalf
of AskAt and its Affiliates, all Regulatory Materials in the Field and in the Territory. 
 4.4 Exclusivity. During the Term, except
as required by (i) the AskAt Outbound Agreements, the [***] Agreements or the [***] License Agreements, or (ii) any other agreements set forth on Schedule 7.2(e)(i), AskAt shall not, and shall cause its Affiliates not to, Exploit
any EP4 Antagonist in the Field in the Territory. For clarity, AskAt may Exploit any EP4 Antagonist in the Retention Field worldwide. 
 4.5
Further Acts. AskAt shall, and shall cause its Affiliates, to take such actions, including making such filings or executing or delivering such documents, instruments and agreements, as Arrys or any of its Affiliates may reasonably request in
writing from time to time to perfect the licenses and assignments set forth in this Article 4 or otherwise to carry out the purposes and intents of this Agreement. Arrys shall reimburse AskAt its reasonable, documented out-of-pocket expenses incurred in compliance with this Section 4.5. 

ARTICLE 5 
 FINANCIALS

 5.1 Initiation Fee. AskAt shall invoice Arrys for the Initiation Fee as reasonably practicable following the Effective Date
and Arrys shall pay the Initiation Fee within [***] after receipt of such invoice. The “Initiation Fee” is a one-time, non-refundable, non-creditable payment of [***]. For the avoidance of doubt, the Initiation Fee is payable only once. 

  
 16 

 5.2 Development Milestones. 

(a) 007 Development Milestone. Arrys shall provide AskAt with written notice of the first achievement of the 007 Development Milestone
within [***] after the sooner to occur of (i) the first achievement thereof by Arrys or any of its Affiliates or (ii) Arrys obtains knowledge of the achievement of the 007 Development Milestone by a Arrys Sublicensee by virtue of clause
(a) of the definition thereof. AskAt shall invoice Arrys for the 007 Development Milestone Fee following receipt of such written notice as soon as reasonably practicable and Arrys shall pay the 007 Development Milestone Fee within [***] after
receipt of such invoice. The “007 Development Milestone Fee” is a one-time, non-refundable, non-creditable
payment of [***]. For the avoidance of doubt, the 007 Development Milestone Fee is payable only once. 
 (b) 008 Development
Milestone. Arrys shall provide AskAt with written notice of the first achievement of the 008 Development Milestone within [***] after the sooner to occur of (i) the first achievement thereof by Arrys or any of its Affiliates or
(ii) Arrys obtains knowledge of the achievement of the 008 Development Milestone by a Arrys Sublicensee by virtue of clause (a) of the definition thereof. AskAt shall invoice Arrys for the 008 Development Milestone Fee following receipt of
such written notice as soon as reasonably practicable and Arrys shall pay the 008 Development Milestone Fee within [***] after receipt of such invoice. The “008 Development Milestone Fee” is a
one-time, non-refundable, non-creditable payment of [***]. For the avoidance of doubt, the 008 Development Milestone Fee is
payable only once. 
 5.3 Commercial Milestone Payments. 

(a) Arrys shall make each of the one-time commercial milestone payments indicated below to AskAt when
annual worldwide Net Sales of all 007 Composition Products that are Royalty-Bearing Products (“007 Composition Royalty-Bearing Products”) or 008 Composition Products that are Royalty-Bearing Products (“008 Composition
Royalty-Bearing Products”) in the Territory in a given Calendar Year first reach the dollar values indicated below during the Term. If more than one (1) such milestone event is achieved in the same Calendar Year with respect to 007
Composition Royalty-Bearing Products or 008 Composition Royalty-Bearing Products, all the applicable milestone payments shall be due with respect to 007 Composition Royalty-Bearing Products or 008 Composition Royalty-Bearing Products, respectively.
By way of example, if all 007 Composition Royalty-Bearing Products achieve Net Sales in the Territory of [***] during a Calendar Year, and Arrys has not previously made a milestone payment with respect to 007 Composition Royalty-Bearing Products
pursuant to this Section 5.3(a), then Arrys shall pay AskAt a milestone payment of (i) [***] and (ii) [***] simultaneously for the first and second milestone events identified below. For the avoidance of doubt, (i) each milestone
payment set forth in this Section 5.3(a) is payable only once with respect to 007 Composition Royalty-Bearing Products and only once with respect to 008 Composition Royalty-Bearing Products and (ii) Net Sales of 007 Composition
Royalty-Bearing Products and Net Sales of 008 Composition Royalty-Bearing Products shall not be aggregated for purposes of achieving the milestone events indicated below. 
  

					
		  	Commercial Milestone Event, payable once for all 007 Composition Royalty-Bearing Products	  	Milestone Payment
(US$)
	 (1)
	  	Worldwide annual Net Sales of [***]	  	[***]
			
	 (2)
	  	Worldwide annual Net Sales of [***]	  	[***]

  
 17 

					
	 (3)
	  	Worldwide annual Net Sales of [***]	  	[***]
			
	 (4)
	  	 Worldwide annual Net Sales of [***]
	  	 [***]

			
		  	Commercial Milestone Event, payable once for all 008 Composition Royalty-Bearing Products	  	Milestone Payment
(US$)
	 (1)
	  	Worldwide annual Net Sales of [***]	  	[***]
			
	 (2)
	  	Worldwide annual Net Sales of [***]	  	[***]
			
	 (3)
	  	Worldwide annual Net Sales of [***]	  	[***]
			
	 (4)
	  	Worldwide annual Net Sales of [***]	  	[***]

 (b) Notice; Payment. Arrys shall provide AskAt with written notice of the achievement of the milestone
events set forth in this Section 5.3 within [***] after the end of the Calendar Year in which the applicable milestone event was achieved. AskAt shall invoice Arrys following receipt of such written notice as soon as reasonably
practicable and Arrys shall pay the associated milestone payment within [***] of the receipt of such invoice. 
 5.4 Royalties. 

(a) Net Sales Royalty. During the Royalty Term, Arrys shall pay to AskAt royalties equal to [***] (the “Royalty Rate”)
of annual worldwide Net Sales, on a Royalty-Bearing Product-by-Royalty-Bearing Product and
country-by-country basis (the “Net Sales Royalty”). The Net Sales Royalty calculation shall be delivered in writing by Arrys to AskAt within [***] after
the end of each applicable Calendar Quarter and shall include the aggregate gross sales of the Royalty-Bearing Products in the Territory during such Calendar Quarter, the corresponding Net Sales and the calculation of the Net Sales Royalty payment
payable with respect to such Net Sales (each, a “Net Sales Statement”). AskAt shall invoice Arrys following receipt of such written notice as soon as reasonably practicable and Arrys shall pay the associated payment within [***]
after the receipt of such invoice. Each Net Sales Statement provided by Arrys shall be deemed final and not subject to challenge two (2) years after the end of the Calendar Quarter to which such Net Sales Statement relates. In addition to the
foregoing, each Net Sales Statement shall include (i) the amount of Net Sales received by Arrys or its Affiliates with respect to any Licensed Product and the deductions used in computing the related Net Sales Royalty due hereunder and
(ii) the name and address of all Arrys Sublicensees. 
 (b) Third Parties. In no event shall Arrys be required to contribute to,
or otherwise pay for or reimburse, AskAt’s payments to Third Parties from which it has received (sub)licenses as of the Effective Date to intellectual property that claims or covers any Licensed Compound or Licensed Product, if any. 

(c) No Multiple Royalties. The obligation to pay royalties is imposed only once with respect to Net Sales of the same unit of a
Royalty-Bearing Product such that if the Exploitation of any Royalty-Bearing Product is claimed or covered by more than one Valid Claim of the Licensed Patents or encompasses or uses more than one element of Licensed
Know-How, multiple royalties shall not be due. 

  
 18 

 (d) Net Sales Audit Rights. 

(i) Arrys shall maintain (and will ensure that its Affiliates maintain) complete and accurate books and records that fairly
reflect Net Sales, in sufficient detail to enable AskAt to confirm the accuracy of any payments required hereunder, such books and records and accounts will be retained for [***] after the end of Calendar Year to which they relate. 

(ii) AskAt shall have the right to engage, at its own cost and expense, subject to this Section 5.4, an independent
internationally recognized public accounting firm chosen by AskAt and reasonably acceptable to Arrys (which accounting firm shall not be the external auditor of AskAt, shall not have been hired or paid on a contingency basis and shall have
experience auditing pharmaceutical companies) (a “CPA Firm”) to conduct an audit of Arrys for the purposes of confirming Arrys’s compliance with the Net Sales Royalty provisions of this Agreement. 

(iii) The CPA Firm shall be given access to and shall be permitted to examine such books and records of Arrys, and to interview
employees of Arrys, as the CPA Firm shall reasonably request, upon [***] prior written notice having been given by AskAt, during regular business hours, for the sole purpose of determining compliance with the Net Sales Royalty provisions of this
Agreement. Prior to any such examination taking place, the CPA Firm shall enter into a confidentiality agreement reasonably acceptable to Arrys with respect to the Know-How to which they are given access and
shall not contain in its report or otherwise disclose to AskAt or any Third Party any information other than the existence of a discrepancy between the Net Sales Royalty paid by Arrys and the amounts payable hereunder and the amount of such
discrepancy. 
 (iv) The CPA Firm shall discuss its preliminary findings with Arrys prior to the preparation by the CPA firm
of its final report. The CPA Firm shall provide both AskAt and Arrys simultaneously the written report of the CPA Firm with respect to its findings. In the event of any dispute between AskAt and Arrys regarding the findings of any such inspection or
audit, the Parties shall initially attempt in good faith to resolve the dispute amicably between themselves, and if the Parties are unable to resolve such dispute within [***] after delivery to both Parties of the CPA Firm’s report, the Parties
shall select one (1) internationally recognized independent certified public accounting firm (other than the CPA Firm) to resolve the dispute, and such accounting firm’s determination shall be binding on both Parties absent manifest error
by such accounting firm. 
 (v) Within [***] after completion of the CPA Firm’s audit, Arrys shall pay to AskAt any
undisputed deficiency in the Net Sales Royalty amount determined by the CPA Firm, plus interest at the rate set forth in Section 5.7 from the date originally due. If the report of the CPA Firm shows that Arrys overpaid, then Arrys shall
be entitled to off-set such overpayment against any Net Sales Royalty owed to AskAt then or in any subsequent period. If the report of the CPA Firm shows that Arrys underpaid and if such discrepancy exceeds
the greater of [***] of the amount audited or [***], then all the fees and expenses of the CPA Firm in performing such audit shall be paid by Arrys. 

(vi) AskAt’s exercise of its audit rights under this Section 5.4(d) may not (A) be conducted for any
Calendar Quarter more than [***] after the end of such Calendar Quarter to which such books and records pertain, (B) be conducted more than once in any Calendar Year, or (C) be repeated for any Calendar Quarter. 

  
 19 

 (vii) AskAt shall not have the right to audit Arrys Sublicensee(s) directly,
but in connection with an audit of Arrys under this Section 5.4(d), AskAt shall have the right to cause Arrys to audit the applicable Arrys Sublicensee(s) using the CPA Firm conducting the audit under this Section 5.4(d).

 (e) Mode of Payment; Currency Conversion. All payments under this Agreement, shall be made by deposit of U.S. Dollars in the
requisite amount to such bank account as AskAt may from time to time designate by notice to Arrys. For the purpose of calculating any sums due under this Agreement (including the calculation of Net Sales expressed in currencies other than U.S.
Dollars), Arrys shall convert any amount expressed in a foreign currency into U.S. Dollar equivalents using Arrys’s (or its Affiliate’s or Arrys Sublicensee’s standard conversion methodology consistent with U.S. generally
accepted accounting principles (GAAP) or international financial reports standards (IFRS), as applicable, in a manner consistent with such Person’s normal practices used to prepare its audited financial reports; provided that, such
practices use a widely accepted source of published exchange rates. Notwithstanding the foregoing, the currency conversion methodology to be used for calculating any sums due under this Agreement in connection with any sales or other transfers of
Royalty-Bearing Product by any Arrys Sublicensee shall be the methodology agreed to by Arrys and any of its Affiliates with such Arrys Sublicensee. Any reporting of currency conversion hereunder shall reflect the currency conversion methodology
agreed to by Arrys and any of its Affiliates with a Arrys Sublicensee. 
 (f) Blocked Payments. In the event that, by reason of
applicable Laws or regulations in any country, it becomes impossible or illegal for Arrys or its Affiliates to transfer, or have transferred on its behalf, royalties or other payments to AskAt, such royalties or other payments shall be deposited in
local currency in the relevant country to the credit of AskAt in a recognized banking institution designated by AskAt or, if none is designated by AskAt within a period of [***], in a recognized banking institution selected by Arrys. 

(g) Taxes. Where required by Applicable Law, Arrys shall have the right to withhold applicable taxes from any payments to be made by
Arrys to AskAt pursuant to this Agreement; provided that, to the extent allowed by Applicable Law, prior to such withholding, Arrys shall give written notice of its intention to withhold and allow AskAt reasonably sufficient time to provide
any documentation or forms to the applicable Governmental Authority to minimize or eliminate such withholding. Arrys shall provide AskAt with receipts from the appropriate taxing authority for all payments of taxes withheld and paid by Arrys to such
authorities on behalf of AskAt. AskAt shall have the right to appeal to the appropriate taxing authority any such withholding and payment of such taxes. 

(h) No Other Compensation. Other than as explicitly set forth (and as applicable) in this Agreement, Arrys shall not be obligated to
pay any additional fees, milestone payments, royalties or other payments of any kind to or on behalf of AskAt or its Affiliates under this Agreement. 

5.5 Right to Set-off. Either Party shall have the right to deduct from amounts otherwise
payable hereunder to the other Party any amounts payable to such Party (or its Affiliates) from the other Party (or its Affiliates) under this Agreement that have been determined by a final, non-appealable
judgment by a court of competent jurisdiction or otherwise agreed to by the Parties. 

  
 20 

 5.6 Right to terminate. Arrys’s failure to make any undisputed payments required
hereunder, shall be a material breach hereof, subject to Section 10.3(a). 
 5.7 Late payment. Any payment not delivered
on time shall accrue interest from the date due until paid in full at the rate of the lower of [***] or the highest rate allowed under Applicable Laws. 

ARTICLE 6 
 INTELLECTUAL
PROPERTY 
 6.1 Ownership of IP. 

(a) Ownership shall follow inventorship for all Inventions developed, created, conceived or reduced to practice by or on behalf of the Parties
in connection with and during the Term of this Agreement, with inventorship being determined in accordance with United States patent laws (regardless of where the applicable activities occurred). 

(b) Subject to the terms and conditions of this Agreement, Arrys, on behalf of itself and its Affiliates, hereby grants to AskAt and its
Affiliates, a non-exclusive, perpetual, fully paid-up, royalty-free, non-sublicensable, transferable solely as permitted by Section 12.6, license under all
Know-How and Inventions Controlled by Arrys or any of its Affiliates that solely relate to a Licensed Compound, Licensed Product, or Treatment Product and were developed, created, conceived or reduced to
practice solely or jointly by or on behalf of Arrys in connection with this Agreement, in each case, solely to Exploit EP4 Antagonists (i) outside the Territory or (ii) in the Retention Field worldwide; provided that in the event of a
Change of Control of Arrys or any of its Affiliates, the scope of the Know-How and Inventions licensed to AskAt and its Affiliates pursuant to this Section 6.1(b) shall constitute only that Know-How and those Inventions Controlled by Arrys or any of its Affiliates prior to such Change of Control. 

6.2 Prosecution, Maintenance & Enforcement. 

(a) Prosecution & Maintenance of Licensed Technology. 

(i) Except as set forth below in Section 6.2(b), as of the Effective Date and as between the Parties, AskAt shall,
through counsel mutually acceptable to the Parties and directed by AskAt, control the preparation, filing for, and prosecution and maintenance of (including the defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant proceedings originating in a patent office) all intellectual property rights pertaining to the Licensed Technology in the Field in the Territory, provided that AskAt shall
consider in good faith all input received from Arrys regarding such prosecution and maintenance. Arrys shall reimburse AskAt the reasonable out-of-pocket expenses
incurred by AskAt pursuant to this Section 6.2(a)(i) within [***] following receipt of a reasonably detailed invoice therefor; provided that in no event will Arrys be required to reimburse AskAt for any expenses for which a Third Party
is obligated to reimburse AskAt or for which a Third Party previously reimbursed AskAt. 
 (ii) AskAt shall provide Arrys and
Arrys’s patent counsel copies of communications received by AskAt regarding any Licensed Patent. AskAt shall keep Arrys advised of the status of all material communications, notices and actions submitted to or received from the relevant patent
authorities, actual and prospective filings or 

  
 21 

 
submissions regarding Licensed Patents, and shall give Arrys copies of and a reasonable opportunity to review and comment on any such communications, filings and submissions proposed to be sent
to any patent office or judicial body. AskAt shall consider in good faith Arrys’s comments on the communications, filings and submission for the Licensed Patents. 

(iii) If AskAt declines to file for, prosecute or maintain (including defending or prosecuting office actions, prosecutions or
interferences) any Licensed Patent, it shall give Arrys reasonable notice thereof and thereafter, Arrys may, upon written notice to AskAt and at Arrys’s sole cost, control the filing for, prosecution and maintenance of such Licensed Patent
thereafter in accordance with this Section 6.2(a), mutatis mutandis; provided that Arrys shall not exercise any rights under this Section 6.2(a)(iii) with respect to a particular Licensed Patent, if AskAt determined in
its reasonable business judgment that filing for, prosecuting or maintaining (including defending or prosecuting office actions, prosecutions or interferences) such Licensed Patent would not be in AskAt’s best interest. 

(iv) Within [***] after the Effective Date, AskAt shall (to the extent not previously provided) provide Arrys, at Arrys’s
cost, with copies of all documents (including file histories and a [***] report) for the Licensed Patents that are in the file maintained by AskAt’s in-house or outside patent counsel or otherwise
available to AskAt, including any communications, filings and drafts including all electronic versions in Word format as well as written notice of any pending deadlines or communications for such Patents; provided, however, that AskAt shall provide
notice of pending deadlines as promptly as possible after the Effective Date so as to ensure adequate time and coordination with respect to such deadlines. In the event Arrys assumes control of the preparation of, filing for, and prosecution and
maintenance (including the defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant proceedings originating in a patent office) with respect to any Licensed Patents
pursuant to Section 6.2(a)(iii), then AskAt shall, at Arrys’s cost, (A) provide Arrys with copies of any relevant communications, filings, drafts and documents not previously provided to Arrys as well as written notice of any
pending deadlines or communications applicable thereto, and (B) execute and deliver any legal papers reasonably requested by Arrys to effectuate transfer of control of the filing, prosecution and maintenance of such Patents (excluding papers
that transfer any right, title or interest in or to the Licensed Patents other than such control). 
 (b) Prosecution &
Maintenance of Joint Patents. 
 (i) Notwithstanding Section 6.2(a), as of the Effective Date and as between
the Parties, Arrys shall, through counsel mutually acceptable to the Parties and directed by Arrys, control the preparation, filing for, and prosecution and maintenance of (including the defense of any oppositions, interferences, reissue
proceedings, re-examinations and other post-grant proceedings originating in a patent office) all Joint Patents in all fields throughout the world, provided that Arrys shall consider in good faith all
input received from AskAt regarding such prosecution and maintenance. The Parties shall equally share expenses incurred pursuant to this Section 6.2(b)(i), with each Party reimbursing [***] of the other Party’s reasonable out-of-pocket expenses incurred by such other Party pursuant to this Section 6.2(b)(i) within thirty (30) days following receipt of a reasonably detailed
invoice therefor; provided that in no event will Arrys be required to reimburse AskAt for any expenses for which a Third Party is obligated to reimburse AskAt or for which a Third Party previously reimbursed AskAt. 

  
 22 

 (ii) Arrys shall provide AskAt and AskAt’s patent counsel copies of
communications received by Arrys regarding any Joint Patent. Arrys shall keep AskAt advised of the status of all material communications, notices and actions submitted to or received from the relevant patent authorities, actual and prospective
filings or submissions regarding Joint Patents, and Arrys shall give AskAt copies of and a reasonable opportunity to review and comment on any such communications, filings and submissions proposed to be sent to any patent office or judicial body.
Arrys shall consider in good faith AskAt’s comments on the communications, filings and submission for the Joint Patents. 

(iii) If Arrys declines to file for, prosecute or maintain (including defending or prosecuting office actions, prosecutions or
interferences) any Joint Patent, it shall give AskAt reasonable notice thereof and thereafter, AskAt may, upon written notice to Arrys and at AskAt’s sole cost, control the filing for, prosecution and maintenance of such Joint Patent thereafter
in accordance with this Section 6.2(b), mutatis mutandis; provided that AskAt shall not exercise any rights under this Section 6.2(b)(iii) with respect to a particular Joint Patent, if Arrys determined in its
reasonable business judgment that filing for, prosecuting or maintaining (including defending or prosecuting office actions, prosecutions or interferences) such Joint Patent would not be in Arrys’s best interest. 

(iv) In the event AskAt assumes control of the preparation of, filing for, and prosecution and maintenance (including the
defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant proceedings originating in a patent office) with respect to any Joint Patents pursuant to
Section 6.2(b)(iii), then Arrys shall, at AskAt’s cost, (A) provide AskAt with copies of any relevant communications, filings, drafts and documents not previously provided to AskAt as well as written notice of any pending
deadlines or communications applicable thereto, and (B) execute and deliver any legal papers reasonably requested by AskAt to effectuate transfer of control of the filing, prosecution and maintenance of such Patents (excluding papers that
transfer any right, title or interest in or to the Joint Patents other than such control). 
 (c) Other Patents. Except as set forth
above, each Party have the sole right, responsibility and discretion to file, prosecute (including the defense of any oppositions, interferences, reissue proceedings, re-examinations and other post-grant
proceedings originating in a patent office) maintain and enforce intellectual property rights owned or controlled by such Party at its sole cost and expense. 

6.3 Defense and Settlement of Third Party Claims. 

(a) Licensed Compounds and Licensed Products. 

(i) From and after the Effective Date, if a Third Party asserts that a Patent or other right owned by it is infringed by the
Exploitation of any Licensed Compound or Licensed Product in the Field in the Territory, Arrys shall have the first right to control the defense of any such Third Party claims at Arrys’s sole cost and expense and to elect to settle such claims
(except as set forth below). AskAt shall assist 

  
 23 

 
Arrys and cooperate in any such litigation at Arrys’s request, and Arrys shall reimburse AskAt any reasonable, documented
out-of-pocket costs incurred in connection therewith. AskAt may join any defense pursuant to this Section 6.3, with its own counsel, at its sole cost and
expense. Arrys shall not settle or consent to the entry of any judgment in any enforcement action hereunder without AskAt’s prior written consent, not to be unreasonably withheld, conditioned or delayed. 

(ii) Should Arrys fail to defend against any such assertion within [***] prior to the applicable
non-extendable deadline for doing so, AskAt shall have the right to do so, at AskAt’s sole cost and expense; provided that AskAt shall not exercise any rights under this Section 6.3 if Arrys
determined in its reasonable business judgment that defending against the relevant Third Party assertion would not be in Arrys’s best interest. In the event that AskAt exercises rights under this Section 6.3: (i) Arrys shall
reasonably assist AskAt and reasonably cooperate in any such litigation at AskAt’s request, and AskAt shall reimburse Arrys any reasonable, documented out-of-pocket
costs incurred in connection therewith, (ii) Arrys may join any such defense brought by AskAt pursuant to this Section 6.3, with its own counsel, at its sole cost and expense, and (iii) AskAt shall not settle any assertions or
consent to the entry of any judgment that adversely affects Arrys’s rights in any litigation being defended hereunder without Arrys’s prior written consent, not to be unreasonably withheld, conditioned or delayed. 

(b) General. Without limiting the foregoing in this Section 6.3, 

(i) (A) either party shall give the other party prompt written notice of any allegation by any Third Party that a Patent or
other right owned by it is infringed by the Exploitation of any Licensed Compound or Licensed Product and (B) either party shall pay to the other party any amounts due under this Section 6.3 within [***] of the date of the relevant
invoice; and 
 (ii) if a Party is obligated under Section 8.1 or Section 8.2 to indemnify the other
Party (including any Arrys Indemnitee with respect to indemnification of Arrys and including any AskAt Indemnitee with respect to indemnification of AskAt) with respect to a Third Party assertion of infringement, then the process described in
Section 8.3 shall govern the procedure for defending against such claim rather than this Section 6.3. 
 6.4
Enforcement. 
 (a) In the event that (i) AskAt or Arrys becomes aware of any actual or suspected infringement of any Licensed
Patent in the Field in the Territory, (ii) any Licensed Patent is challenged in any action or proceeding (other than any interferences, oppositions, reissue proceedings or re-examinations, which are
addressed in Section 6.2) or (iii) AskAt or Arrys receives a Notice of Paragraph IV Patent certification as described in Section 6.6(c) with respect to a Licensed Patent, such Party shall notify the other Party promptly
(an “Infringement Notice”), and following such Infringement Notice, the Parties shall confer. To the extent permitted by Applicable law, Arrys shall have the first right to defend any such action or proceeding or bring an
infringement action with respect to such infringement at its own expense, in its own name and entirely under its own direction and control, or settle any such action or proceeding by sublicense (including, at Arrys’s sole discretion, granting a
sublicense, covenant not to sue or other right with respect to a compound or product (including a Generic Product) in the Field in the Territory). AskAt shall, at Arrys’s costs, assist Arrys and shall agree to be

  
 24 

 
named or to join in any action or proceeding being defended or prosecuted if so requested. Even if AskAt elects to be represented by legal counsel or if AskAt is required to be named in or joined
in such action or proceeding or is joined in such action or proceeding at Arrys’s request, Arrys shall bear all of AskAt’s related and reasonable legal costs and expenses arising out of this Section 6.4(a). 

(b) Should Arrys fail to defend against any action or proceeding or bring an infringement action as permitted above within [***] following the
date of the relevant Infringement Notice, AskAt shall have the right to do so, at AskAt’s sole cost and expense; provided that AskAt shall not exercise any rights under this Section 6.4(b), if Arrys determined in its reasonable
business judgment that defending against the relevant action or proceeding or bringing an infringement action would not be in Arrys’s best interest. In the event that AskAt exercises rights under this Section 6.4(b): (i) Arrys shall
reasonably assist AskAt in any action or proceeding being defended or prosecuted if so requested, and shall be named in or join such action or proceeding if requested by AskAt; AskAt shall reimburse Arrys any reasonable, documented out-of-pocket costs incurred in connection therewith, (ii) Arrys may join any such action or proceeding being defended or prosecuted by AskAt pursuant to this
Section 6.4(b), with its own counsel, at its sole cost and expense and (iii) AskAt shall not settle any assertions or consent to the entry of any judgment that adversely affects Arrys’s rights in any action or proceeding being
defended or prosecuted without Arrys’s prior written consent, not to be unreasonably withheld, conditioned or delayed. 
 (c)
Damages. In the event that either Party exercises the rights conferred in this Section 6.4 and recovers any damages, payments or other sums in such action or proceeding or in settlement thereof, such damages or other sums
recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties in connection therewith (including attorney’s fees). If such
recovery is insufficient to cover all such costs and expenses of both Parties, the Parties shall be paid pro-rata in proportion to the total amount of costs and expenses incurred by each Party. If after such
reimbursement any funds shall remain from such damages or other sums recovered, such funds shall be retained by Arrys; provided, however, the remaining recovery shall be treated as Net Sales hereunder and subject to the terms and conditions
set forth in Section 5.4. 
 6.5 Trademarks. Arrys shall solely own all right, title and interest in and to any
trademarks (hereinafter “Arrys’s trademarks”) adopted for use with the Licensed Products in the Field in the Territory, and shall be responsible for the registration, filing, maintenance and enforcement thereof. AskAt shall not at any
time do or authorize to be done any act or thing which is likely to materially impair the rights of Arrys’s trademarks, and shall not at any time claim any right of interest in or to such marks or the registrations or applications therefor.
AskAt shall not use Arrys’s trademarks or any confusingly similar trademarks in a manner that might amount to infringement, dilution, unfair competition or passing off of any of Arrys’s trademarks without Arrys’s consent. 

6.6 Patent Extensions; Orange Book Listings; Patent Certifications. 

(a) Patent Term Extension. If elections with respect to obtaining patent term extension or supplemental protection certificates or
their equivalents in any country with respect to any Licensed Product becomes available, the first Party to receive Regulatory Approval therefor shall have the sole right to decide whether to file for patent term extension or supplemental protection
certificates or their equivalents and to determine which issued patent to extend. Each Party shall, at its cost, cooperate with the other so as to enable the relevant Party 

  
 25 

 
to exercise its rights under this Section 6.6(a). Such cooperation includes promptly executing all documents, requiring inventors to be available to discuss and review any filings,
and requiring inventors, subcontractors, employees, consultants and agents of a Party to execute all documents, as reasonable and appropriate so as to enable to the relevant Party to exercise its rights under this Section 6.6(a). In the
event that the first Party to receive regulatory approval for a Licensed Product does not exercise its rights under this Section 6.6(a) prior to receipt of Regulatory Approval for a Licensed Product by the other Party, such other Party
may exercise all rights under this Section 6.6(a). as if such Party were the first to receive Regulatory Approval of any Licensed Product. 

(b) Regulatory Exclusivity and Orange Book Listings. With respect to regulatory exclusivity periods (such as orphan drug exclusivity
and any available pediatric extensions), Arrys shall have the sole responsibility and right to seek and maintain all such regulatory exclusivity periods that may be available for the Licensed Products in the Field in the Territory. Arrys shall have
the sole right to make all filings in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations and all equivalents in any country in the Territory with respect to the Licensed Products in the Field in the Territory. 

(c) Notification of Patent Certification. AskAt and Arrys shall each notify and provide the other Party with copies of any notice of a
Paragraph IV Patent Certification (including any associated documents) by a Third Party filing an ANDA, an application under §505(b)(2) of the FD&C Act (as amended or any replacement thereof), or any other similar patent certification by a
Third Party, and any foreign equivalent thereof. Such notification and copies shall be provided to the other Party within [***] after receipt of such notification and shall be sent to the address set forth in Section 12.3. 

ARTICLE 7 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

7.1 Mutual Representations, Warranties and Covenants. Each Party hereby represents and warrants to the other Party as of the Effective
Date, and covenants, as applicable, as a material inducement for such other Party’s entry into this Agreement, as follows: 
 (a)
Corporate Existence and Power. It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal
right to own and operate its property and assets and to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it hereunder. 

(b) Authority and Binding Agreement. (i) It has the corporate power and authority and the legal right to enter into this Agreement
and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and (iii) this
Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms. 

  
 26 

 (c) No Conflict. It is not a party to and shall not enter into any agreement that
would prevent it from granting the rights or exclusivity granted or intended to be granted to the other Party under this Agreement or performing its obligations under this Agreement. 

(d) Bankruptcy; Insolvency. It is not aware of any action or petition, pending or otherwise, for bankruptcy or insolvency of such Party
or its Affiliates or subsidiaries in any state, country or other jurisdiction, and it is not aware of any facts or circumstances that could result in such Party becoming or being declared insolvent, bankrupt or otherwise incapable of meeting its
obligations under this Agreement as they become due in the ordinary course of business. 
 (e) No Debarment. Such Party is not
debarred, has not been convicted, and is not subject to debarment or conviction pursuant to Section 306 of the FD&C Act. In the course of the Research or Development of Licensed Compounds or Licensed Products, such Party has not, to its
knowledge, used prior to the Effective Date, and shall not use, during the Term, any employee, consultant, agent or independent contractor who has been debarred by any Regulatory Authority, or, to such Party’s knowledge, is the subject of
debarment proceedings by a Regulatory Authority or has been convicted pursuant to Section 306 of the FD&C Act. 
 (f) Compliance
with Applicable Law. Each Party shall comply with the Applicable Law in the course of performing its obligations or exercising its rights pursuant to this Agreement. Without limiting the foregoing, Arrys shall comply with Applicable Law related
to recalls of, and safety and reporting requirements with respect to, Licensed Products Exploited by Arrys. 
 7.2 Representations,
Warranties and Covenants by AskAt. AskAt hereby represents, warrants and covenants to Arrys as of the Effective Date, and covenants to Arrys, as applicable, as material inducement for Arrys’s entry into this Agreement and the grant of licenses
and rights from AskAt to Arrys hereunder, as follows: 
 (a) No IP Conflicts. As of the Effective Date, neither AskAt nor any of its
Affiliates has entered into any agreement (other than agreements with subcontractors) granting any right, interest or claim in or to, any Licensed Technology to any Third Party that would conflict with the licenses and other rights granted to Arrys
under this Agreement. All intellectual property rights owned by AskAt and its Affiliates relating to the Licensed Compounds or Licensed Products are Controlled by AskAt and are included in the Licensed Technology. Following the Effective Date, AskAt
shall not enter into any agreement with any Affiliate or Third Party that conflicts with or contradicts the terms and conditions set forth in this Agreement, including any agreement that would limit the grant of licenses or rights hereunder to the
Licensed Technology. All Licensed Technology existing as of the Effective Date is exclusively owned by AskAt, and is free and clear of any (i) liens, charges, security interests, and encumbrances or licenses and (ii) claims or covenants
that would conflict with or limit the scope of any of the rights or licenses granted to Arrys hereunder or would give rise to any Third Party claims for payment against Arrys or its Affiliates. Except as set forth on Schedule 7.2(a), none of
the Licensed Technology existing as of the Effective Date is in-licensed by AskAt. 
 (b) No
Notice of Infringement or Misappropriation. As of the Effective Date, (i) AskAt has not received and is not aware of any written notice from any Third Party asserting or alleging that any research, development, use, manufacture, sale, offer
for sale, importation or exportation of Licensed Technology, Licensed Compounds or Licensed Products has infringed 

  
 27 

 
or misappropriated, or would infringe or misappropriate, the intellectual property rights of any Third Party, and (ii) no claim is pending, and AskAt and its Affiliates and, to AskAt’s
knowledge, any Third Party collaborator, has not received from a Third Party notice of a claim or threatened claim to the effect that any granted Patent within the Licensed Technology under this Agreement is invalid or unenforceable. Additionally,
to AskAt’s knowledge, there is no unauthorized use, infringement or misappropriation of any Licensed Technology by any Third Party as of the Effective Date. 

(c) No Misappropriation. To the knowledge of AskAt, as of the Effective Date, (i) the development, creation, conception and
reduction to practice of any inventions and, to the knowledge of AskAt, the use, development, creation, conception and reduction to practice of any other Know-How within Licensed Technology have not
constituted or involved the misappropriation of trade secrets or other rights or property of any Third Party, and (ii) no employee, consultant, agent or independent contractor of AskAt, or Third Party, has misappropriated any Licensed
Technology. To the knowledge of AskAt, as of the Effective Date, no intellectual property right of a Third Party would be infringed, misappropriated or otherwise violated by use of the Licensed Technology or the Exploitation of the Licensed
Compounds or Licensed Products. 
 (d) Licensed Technology. To the knowledge of AskAt, as of the Effective Date, the Patents set
forth on Exhibit A under the heading Composition Patents are the only Patents within the Licensed Technology existing as of the Effective Date that claim or cover the Licensed Compounds. The Licensed Patents have been diligently prosecuted in
the respective patent offices indicated thereon with respect to each Patent in accordance with Applicable Law, have been filed and maintained properly and correctly and all applicable fees have been paid on or before the due date for payment, and to
the knowledge of AskAt and its Affiliates, is not invalid or unenforceable, in whole or in part. The Patents set forth on Exhibit A collectively represent the only Patents within AskAt’s or any of its Affiliates’ Control relating to
the Licensed Compounds or Licensed Products, or the Exploitation thereof, as of the Effective Date. 
 (e) Third Party Agreements.

 (i) Schedule 7.2(e)(i) contains a complete and accurate list of each license agreement, material transfer
agreement, sales and purchase agreement, collaboration agreement or research agreement which is effective as of the Effective Date between each of AskAt or any of its Affiliates with any Third Party relating to any of the Licensed Technology,
Licensed Compounds or Licensed Products, other than agreements with subcontractors for the manufacturing of Drug Substance. 

(ii) To the knowledge of AskAt, Schedule 7.2(e)(ii) contains a complete and accurate list of all material agreements
between or among [***] and any Third Party that relate to any of the Licensed Technology, Licensed Compounds or Licensed Products, other than agreements with subcontractors for the manufacturing of Drug Substance. 

(f) Disclosure of Know-How. Licensed Know-How provided
by or on behalf of AskAt to Arrys or its agents or representatives prior to or on the Effective Date with respect to this Agreement was and is true, accurate and complete in all material respects, and AskAt has not disclosed, failed to disclose or
caused to be disclosed any Know-How or data that could reasonably be expected to be misleading in any material respect. 

  
 28 

 (g) Assignments. 

(i) AskAt has secured from all of its employees who have contributed to the development, creation, conception or invention of
any of the Licensed Technology a written agreement assigning to AskAt all rights to such developments, creations, conceptions or inventions, or Licensed Technology, and as of the Effective Date, AskAt has not received any written communication
challenging AskAt’s ownership or right to the Licensed Technology, unless such an agreement with the inventor is not required under Applicable Law for ownership in such Licensed Technology to vest in AskAt. 

(ii) To AskAt’s knowledge, [***] has secured from all of its employees, consultants, contractors and other Persons who
have contributed to the development, creation, conception or invention of any of the Licensed Technology a written agreement assigning to [***] all rights to such developments, creations, conceptions or inventions, or Licensed Technology, and [***]
has not received any written communication challenging [***] ownership or right to the Licensed Technology, unless such an agreement with the inventor is not required under Applicable Law for ownership in such Licensed Technology to vest in [***].

 (h) All Material Information Provided. AskAt has provided or made available to Arrys or its agents or representatives all material
information that is in AskAt’s or its Affiliates’ possession concerning the Licensed Compounds, the Licensed Products and the Licensed Technology, including relevant to the safety or efficacy of such Licensed Compounds and Licensed
Products, and all material Regulatory Materials and other material correspondence with Regulatory Authorities relating to any such Licensed Compound or Licensed Product, and all such information is accurate, complete and true in all material
respects; 
 (i) Conduct of Research and Development. AskAt has conducted all Research and Development of Licensed Compounds and
Licensed Products in accordance with all Applicable Law. To the knowledge of AskAt, [***] has conducted all Research and Development of Licensed Compounds and Licensed Products in accordance with all Applicable Law. 

(j) No Third Party Consent Rights. AskAt may enter into this Agreement without obtaining, or seeking, consent from, or providing notice
to, any Third Party. AskAt’s execution of this Agreement absent any such consent or notice does not conflict with any agreement between or among AskAt and any Third Party or Third Parties. 

7.3 Additional Covenants Regarding Agreements with Third Parties. AskAt agrees that during the Term: 

(a) Without Arrys’s prior written consent, AskAt shall not modify or amend any [***] Agreement or AskAt Outbound Agreement in a manner
that would reduce or otherwise limit any of the rights granted to Arrys under this Agreement or impose additional obligations on Arrys. AskAt shall provide Arrys with a copy of any amendment, side letter or other modification to any Ask-At [***] Agreement or AskAt Outbound Agreement; 
 (b) AskAt shall use commercially reasonable efforts
to prevent the modification or amendment to any [***] License Agreement in a manner that would reduce or otherwise limit any of the rights granted to Arrys under this Agreement or impose additional obligations on Arrys. AskAt shall use commercially
reasonable efforts to provide Arrys with a copy of any amendment, side letter or other modification to any [***] License Agreement; 

  
 29 

 (c) Without Arrys’s prior written consent, AskAt shall not terminate any [***]
Agreement in whole or in part if doing so would reduce or otherwise limit any of the rights granted to Arrys under this Agreement; 
 (d)
AskAt shall use commercially reasonable efforts to prevent the termination of any [***] License Agreement in whole or in part if the termination thereof would reduce or otherwise limit any of the rights granted to Arrys under this Agreement; 

(e) Without Arrys’s prior written consent, AskAt shall not exercise or fail to exercise any of AskAt’s rights or obligations under
any [***] Agreement or AskAt Outbound Agreement in a manner that would reduce or otherwise limit any of the rights granted to Arrys under this Agreement or impose additional obligations on or have an adverse effect on Arrys; and, at the reasonable
request of Arrys, AskAt shall exercise such rights and perform obligations that relate to Licensed Compounds, Licensed Products or Arrys’s rights thereunder in such manner as Arrys requests and is permitted under any of the AskAt-RaQualia
Agreements or AskAt Outbound Agreements; 
 (f) AskAt shall use commercially reasonable efforts to cause each party (other than AskAt) to
any [***] Agreement, [***] License Agreement or AskAt Outbound Agreement to exercise or, not to fail to exercise, any rights or obligations under any such Agreement in a manner that would reduce or otherwise limit any of the rights granted to Arrys
under this Agreement or impose additional obligations on Arrys; 
 (g) AskAt shall promptly provide Arrys with copies of all reports and
other material communications that AskAt provides to any party under any of the [***] Agreements or the AskAt Outbound Agreements, provided that AskAt may redact any confidential technical or financial information that does not relate to
Licensed Compounds, Licensed Products or Arrys’s rights hereunder; 
 (h) (i) Without limiting Section 7.3(g), AskAt shall
promptly provide Arrys with copies of all safety data Controlled by AskAt or any of its Affiliates or any other licensee of AskAt that satisfies each of the following requirements: (A) relates to any Licensed Compound or Licensed Product and
(B) could reasonably be expected to affect development of Licensed Compounds or Licensed Products in the Field in the Territory. Arrys may use such data solely for developing, and having Third Parties develop for Arrys’s benefit, Licensed
Compounds or Licensed Products. Without limiting the foregoing, in no event may Arrys allow such data to be Exploited in the Retention Field regardless of whether inside or outside the Territory. (ii) Notwithstanding anything herein to the
contrary, following a written request from Arrys, AskAt shall promptly provide Arrys with a copy of all such safety data that relates to any Licensed Compound or Licensed Product and that is required by a Governmental Authority, and Arrys may
disclose such safety data to such Governmental Authority if Arrys is required to do so by any Applicable Law or Governmental Authority; provided that Arrys shall request confidential treatment of such data to the extent allowed under Applicable Law.

 (i) AskAt shall promptly notify Arrys of, and provide a copy of, any material communications that AskAt receives related to any of the
[***] Agreements, [***] License Agreements or AskAt Outbound Agreements (including notices of improvements), provided that AskAt may redact any confidential technical or financial information that does not that relate to Licensed Compounds,
Licensed Products or Arrys’s rights hereunder; 

  
 30 

 (j) AskAt shall promptly notify Arrys if AskAt knows or reasonably believes that any party
shall not be able to comply with the terms and conditions of any [***] Agreement, [***] License Agreement or AskAt Outbound Agreement and such non-compliance could reasonably be expected to reduce or otherwise
limit any of the rights granted to Arrys under this Agreement or impose additional obligations on Arrys; 
 (k) AskAt shall notify Arrys of,
and provide a copy of, any notices received by AskAt relating to any alleged breach by any party under a [***] Agreement, [***] License Agreement or AskAt Outbound Agreement within [***] after AskAt’s receipt thereof; in addition, if AskAt
should at any time breach a [***] Agreement or AskAt Outbound Agreement or become unable to timely perform its obligations thereunder, or is aware of any party breaching of [***] Agreement, [***] License Agreement or AskAt Outbound Agreement or is
aware that a party thereto has become unable to timely perform its obligations thereunder, and in any such case, such breach or non-performance could reasonably be expected to reduce or otherwise limit any of
the rights granted to Arrys under this Agreement or impose additional obligations on Arrys then AskAt shall immediately notify Arrys; 
 (l)
If AskAt cannot cure or otherwise resolve any alleged breach by AskAt under an [***] Agreement or AskAt Outbound Agreement and such breach could reasonably be expected to reduce or otherwise limit any of the rights granted to Arrys under this
Agreement or impose additional obligations on Arrys, AskAt shall so notify Arrys within [***] of AskAt’s first becoming aware of such inability, which shall not be less than [***] prior to the expiration of the cure period under such AskAt
Third Party Agreement; provided that AskAt shall use commercially reasonable efforts to cure or otherwise resolve any such alleged breach; 

(m) If AskAt is aware of any alleged breach by [***] under a [***] Agreement or [***] License Agreement and such breach could reasonably be
expected to reduce or otherwise limit any of the rights granted to Arrys under this Agreement or impose additional obligations on Arrys, AskAt shall so notify Arrys within five (5) Business Days of AskAt’s first becoming aware of such
inability; 
 (n) In the event of any alleged breach by AskAt under a [***] Agreement or AskAt Outbound Agreement that could reasonably be
expected to reduce or otherwise limit any of the rights granted to Arrys under this Agreement or impose additional obligations on Arrys, if AskAt has not cured or otherwise resolved any such alleged breach at least [***] prior to the expiration of
the cure period under such [***] Agreement or AskAt Outbound Agreement, then AskAt shall immediately notify Arrys and Arrys, in its sole discretion, shall be permitted to cure such breach under such [***] Agreement or AskAt Outbound Agreement in
accordance with the terms and conditions of such [***] Agreement or AskAt Outbound Agreement or otherwise resolve such breach directly with the other party to such [***] Agreement or AskAt Outbound Agreement; and, if Arrys pays any amounts owed or
alleged to be owed by AskAt, Arrys may deduct such amounts from milestone payments and royalties Arrys is required to make to AskAt hereunder; 

(o) In the event of any alleged breach by [***] under a [***] Agreement or [***] License Agreement that could reasonably be expected to reduce
or otherwise limit any of the rights granted to Arrys under this Agreement or impose additional obligations on Arrys, AskAt shall use commercially reasonable efforts to cause [***] to cure or otherwise resolve any such

  
 31 

 
alleged breach at least [***] prior to the expiration of the cure period under such [***] Agreement or [***] License Agreement and if such alleged breach has not been cured or otherwise resolved
at least [***] prior to the expiration of the relevant cure period under this applicable agreement, then AskAt shall immediately notify Arrys and the Parties will discuss whether they can take action to cure such breach; and 

(p) In the event that any rights that have been granted to a Third Party with respect to any of the Licensed Technology pursuant to any of the
[***] Agreements, [***] License Agreement or AskAt Outbound Agreement revert to AskAt, or are otherwise come into AskAt’s possession, AskAt shall (i) not grant or otherwise convey any such rights to a Third Party in the Field in the
Territory and (ii) ensure that any grant or other conveyance of such rights to a Third Party outside the Field or outside the Territory are consistent with, and do not reduce or otherwise limit, the rights granted to Arrys under this Agreement.

 7.4 Survival of Arrys’s Rights. The Parties agree that in the event of any termination of any AskAt Third Party Agreement
with respect to any intellectual property rights sublicensed to Arrys hereunder, Arrys shall have any rights available under such Third Party Agreement to become a direct licensee of the licensor under such AskAt Third Party Agreement, and AskAt
shall use its best efforts to assist Arrys in exercising such rights. 
 7.5 No Other Representations or Warranties. EXCEPT AS
EXPRESSLY STATED IN THIS ARTICLE 7, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT,
OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES, WHETHER
ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 
 ARTICLE 8 

INDEMNIFICATION 
 8.1
Indemnification by AskAt. Subject to the remainder of this Article 8, AskAt shall defend, indemnify, and hold Arrys, its Affiliates, subcontractors and Arrys Sublicensees, and each of their respective officers, directors, employees,
and agents (the “Arrys Indemnitees”) harmless from and against any and all liabilities, losses, costs, damages, fees, expenses or other amounts payable to a Third Party claimant, as well as any reasonable attorneys’ fees and
costs of litigation incurred by such Arrys Indemnitees, all to the extent resulting from any claims, suits, proceedings or causes of action brought by or on behalf of such Third Party against such Arrys Indemnitee that arise from or are based
on: (a) the Exploitation of products containing AAT-007 or AAT-008 by AskAt or any of its Affiliates, licensees or sublicensees (other than pursuant to the rights
granted to Arrys or its Affiliates hereunder), (b) a material breach of any of AskAt’s representations, warranties or obligations under this Agreement; (c) a breach of any of the AskAt Third Party Agreements by AskAt or any of its
Affiliates; (d) the willful misconduct or grossly negligent acts of AskAt or its Affiliates; or (e) violation of Applicable Law by any AskAt Indemnitees; excluding, in each case ((a), (b), (c), (d) or (e)), any damages or other amounts for
which Arrys has an obligation to indemnify any AskAt Indemnitee pursuant to Section 8.2. 

  
 32 

 8.2 Indemnification by Arrys. Subject to the remainder of this Article 8, Arrys shall
defend, indemnify, and hold AskAt, its Affiliates, subcontractors, and licensees, and each of their respective officers, directors, employees, and agents (the “AskAt Indemnitees”) harmless from and against any and all liabilities,
losses, costs, damages, fees, expenses or other amounts payable to a Third Party claimant, as well as any reasonable attorneys’ fees and costs of litigation incurred by such AskAt Indemnitees, all to the extent resulting from any claims, suits,
proceedings or causes of action brought by such Third Party against such AskAt Indemnitee that arise from or are based on: (a) the Exploitation of Licensed Compounds or Licensed Products by Arrys or its Affiliates, including product liability
claims arising out of such Exploitation; (b) a material breach of any of Arrys’s representations, warranties or obligations under this Agreement; (c) the willful misconduct or grossly negligent acts of Arrys or its Affiliates or
Arrys’s Sublicensees; (d) violation of Applicable Law by any Arrys Indemnitees; or (e) infringement of a Third Party’s intellectual property rights arising out of use by Arrys or any of its Affiliates of a Arrys trademark;
excluding, in each case ((a), (b), (c), (d) or (e)), any damages or other amounts for which AskAt has an obligation to indemnify any Arrys Indemnitee pursuant to Section 8.1. 

8.3 Indemnification Procedures. The Party claiming indemnity under this Article 8 (the “Indemnified Party”)
shall give written notice to the Party from whom indemnity is being sought (the “Indemnifying Party”) promptly after learning of the claim, suit, proceeding or cause of action for which indemnity is being sought
(“Claim”). The Indemnifying Party’s obligation to defend, indemnify, and hold harmless pursuant to Section 8.1 or Section 8.2, as applicable, shall be reduced to the extent the Indemnified Party’s
delay in providing notification pursuant to the previous sentence results in material prejudice to the Indemnifying Party; provided, however, that the failure by an Indemnified Party to give such notice or otherwise meet its obligations under
this Section 8.3 shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement. At its option, the Indemnifying Party may assume the defense and have exclusive control, at its own expense, of any Claim
for which indemnity is being sought by giving written notice to the Indemnified Party within [***] after receipt of the notice of the Claim, provided that (a) it agrees to indemnify the Indemnified Party from and against all losses the
Indemnified Party may suffer arising out of the Claim; (b) the Claim involves only money damages and does not seek an injunction or other equitable relief against the Indemnified Party; (c) the Claim does not relate to any criminal or
regulatory enforcement proceeding; and (d) the Indemnifying Party conducts the defense of the Claim diligently. The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party’s expense, in
connection with the defense. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense; provided, however, the Indemnifying Party shall have the right to assume and conduct the
defense of the Claim with counsel of its choice. The Indemnifying Party shall not settle any Claim that adversely affects the Indemnified Party’s rights without the prior written consent of the Indemnified Party, not to be unreasonably
withheld, conditioned or delayed, unless the settlement involves only the payment of money. The Indemnified Party shall not settle any such Claim that adversely affects the Indemnifying Party’s rights without the prior written consent of the
Indemnifying Party, which consent shall not be unreasonably withheld, conditioned or delayed. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against, and
consent to the entry of any judgment or enter into any settlement with respect to the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the
Indemnifying Party in connection therewith), and (ii) the Indemnified Party reserves any right it may have under this Article 8 to obtain indemnification from the Indemnified Party. 

  
 33 

 8.4 Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER
FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, EXEMPLARY OR INDIRECT DAMAGES OF ANY KIND ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT OR ANY CLAIMS ARISING HEREUNDER, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN
CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 8.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT
(A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 8.1 OR SECTION 8.2, (B) DAMAGES AVAILABLE IN THE CASE OF A PARTY’S FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, OR (C) DAMAGES
AVAILABLE TO A PARTY FOR A BREACH BY THE OTHER PARTY OF ARTICLE 4 OR THE CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 9. 

8.5 Insurance. During the Term, Arrys shall, at its individual sole expense, obtain and maintain commercially reasonable insurance or
maintain a commercially reasonable program of self-insurance. Each Party shall also maintain any mandatory insurance, including but not limited to workers compensation coverage, in accordance with all Applicable Laws and regulations. Each Party
shall provide to the other Party, on request, certificates of insurance evidencing the minimum required insurance, including notice of cancellation to be provided in accordance with the terms of the insurance policies. 

ARTICLE 9 

CONFIDENTIALITY 
 9.1
Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party shall keep confidential and shall not publish or otherwise disclose or use for
any purpose other than as provided for in this Agreement any information and materials provided to it by or on behalf of the other Party or its Affiliates or generated pursuant to this Agreement (collectively, “Confidential
Information”). For clarity, Confidential Information of a Party or its Affiliates shall include, without limitation, all information and materials disclosed by such Party or its Affiliates or their respective designees that (a) is
marked as “Confidential,” “Proprietary” or with similar designation at the time of disclosure or (b) by its nature can reasonably be expected to be considered Confidential Information by the recipient. Information disclosed
orally shall not be required to be identified as such to be considered Confidential Information. The terms of this Agreement shall be deemed to be the Confidential Information of both Parties. Notwithstanding the foregoing, Confidential Information
shall not include any information to the extent that it can be established by written documentation by the receiving Party that such information: 

(a) was already known to the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has
expired or an exception is applicable under the relevant agreement pursuant to which such obligation was established), at the time of disclosure; 

(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 

  
 34 

 (c) became generally available to the public or otherwise part of the public domain after
its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was independently
developed by the receiving Party as demonstrated by written documentation prepared contemporaneously with such independent development; or 

(e) was disclosed to the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has expired
or an exception is applicable under the relevant agreement pursuant to which such obligation was established), by a Third Party who had no obligation to the disclosing Party not to disclose such information to others. 

9.2 Authorized Disclosure. Except as expressly provided otherwise in this Agreement, each Party may use and disclose Confidential
Information of the other Party solely as follows: 
 (a) under appropriate confidentiality provisions substantially equivalent to those in
this Agreement: 
 (i) in connection with the performance of its obligations or as reasonably necessary or useful in the
exercise of its rights under this Agreement, including the right to grant licenses or sublicenses as permitted hereunder; 

(ii) in the case of Arrys as the receiving Party, to actual or potential (sub)licensees, acquirers or assignees, collaborators,
investment bankers, investors or lenders, in each case, on a need to know basis; 
 (iii) in the case of AskAt as the
receiving Party, to actual or potential acquirers or assignees, collaborators, investment bankers, investors or lenders, in each case, on a need to know basis; and 

(iv) in the case of AskAt as the receiving Party, to actual or potential licensees (including an actual or potential licensee
who is a Arrys Sublicensee coming into a direct license as provided for in this Agreement) solely as is reasonably necessary for each such disclosee to conduct technical or legal due diligence in connection with the proposed transaction with AskAt;
provided that in no event shall such disclosure include any Confidential Information of Arrys other than the scope of Licensed Technology, Licensed Compounds, Licensed Products, in the Field and in the Territory, 

(b) to the extent such disclosure is to a Governmental Authority as reasonably necessary in filing or prosecuting Patent, copyright and
trademark applications, prosecuting or defending litigation, complying with applicable governmental regulations with respect to performance under this Agreement, obtaining Regulatory Approval or fulfilling
post-approval regulatory obligations for the Licensed Compounds or Licensed Products, or otherwise required by Applicable Law; provided, however, that if a Party is required by Applicable Law to make
any such disclosure of the other Party’s Confidential Information it shall, except where impracticable for necessary disclosures, give reasonable advance notice to the other Party of such disclosure requirement and, in each of the foregoing,
shall use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed and shall only disclosed that Confidential Information that is required to be disclosed; 

  
 35 

 (c) to advisors (including lawyers and accountants) on a need to know basis, in each case
under appropriate confidentiality provisions or professional standards of confidentiality substantially equivalent to those of this Agreement; or 

(d) to the extent mutually agreed to by the Parties. 

In the event that a receiving Party discloses Confidential Information of the other Party pursuant to the foregoing provisions of this
Section 9.2, the receiving Party shall be primarily liable to the other Party for any act or omission of a disclosee to whom the receiving Party provides the disclosing Party’s Confidential Information to the same extent as if such
act or omission of a disclose were an act or omission of the receiving Party. Notwithstanding the foregoing, the Parties shall agree upon a joint press release to announce this Agreement in a form to be mutually agreed by the Parties; thereafter,
each Party may each disclose to Third Parties the information contained in such press release without the need for further approval by the other. Notwithstanding the foregoing, if a Party is required by Applicable Law to make a disclosure of the
terms of this Agreement in a filing with or other submission to the SEC or foreign equivalent, any stock exchange or market, including publicly disclosing or filing this Agreement as a “material agreement” in accordance with Applicable
Laws or applicable stock exchange regulations, and (A) such Party has provided copies of the disclosure to the other Party as far in advance of such filing or other disclosure as is reasonably practicable under the circumstances, (B) such
Party has promptly notified the other Party in writing of such requirement and any respective timing constraints, and (C) such Party has given the other Party a reasonable time under the circumstances from the date of notice by such Party of
the required disclosure to comment upon, request confidential treatment or approve such disclosure, then such Party shall have the right to make such public disclosure at the time and in the manner reasonably determined by its counsel to be required
by Applicable Law. Notwithstanding anything to the contrary herein, it is hereby understood and agreed that if a Party seeking to make a disclosure to the SEC as set forth in this Section 9.2, and the other Party provides comments within
the respective time periods or constraints specified herein or within the respective notice, the Party seeking to make such disclosure or its counsel, as the case may be, shall in good faith (1) consider incorporating such comments and
(2) use reasonable efforts to incorporate such comments, limit disclosure or obtain confidential treatment to the extent reasonably requested by the other Party. Each Party shall have the right to issue additional press releases or to make
public disclosures with the prior written agreement of the other Party. 
 9.3 Attorney-Client
Privilege. Neither Party is waiving, nor shall be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges as a
result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the receiving Party, regardless of whether the disclosing Party
has asserted, or is or may be entitled to assert, such privileges and protections. The Parties: (a) share a common legal and commercial interest in such disclosure that is subject to such privileges and protections; (b) are or may become
joint defendants in proceedings to which the information covered by such protections and privileges relates; (c) intend that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding
to which the disclosing Party’s Confidential Information covered by such protections and privileges relates; and (d) intend that after the Effective Date both the receiving Party and the disclosing Party shall have the right to assert such
protections and privileges. 

  
 36 

 ARTICLE 10 

TERM AND TERMINATION 
 10.1
Term. This Agreement shall commence on the Effective Date and, unless earlier terminated pursuant to this Article 10, shall expire on a country-by-country
basis and Licensed Product-by-Licensed Product basis on the expiration date in such country of Royalty Term with respect to such Licensed Product in such country (the
“Term”). Following the end of the Term for any such Licensed Product in such country by expiration (but not termination), the license granted to Arrys under Section 4.1 shall become non-exclusive, perpetual, irrevocable,
fully paid-up and royalty-free. 
 10.2 Termination by Arrys. 

(a) Arrys shall have the right for any or no reason to terminate this Agreement upon [***] prior written notice to AskAt. 

(b) Arrys shall have the right to terminate Section 6.1(b) upon written notice to AskAt if AskAt or any of its Affiliates
materially breaches any of its obligations under this Agreement and, after receiving written notice from Arrys identifying such material breach by AskAt in reasonable detail, fails to cure such material breach within [***] from the date of such
notice; provided that such [***] period shall be extended to [***] if AskAt has commenced and is continuing good faith efforts to cure such breach but was not able to cure such breach within the initial [***] period. 

10.3 Termination for Breach or Insolvency. 

(a) Termination by AskAt. AskAt shall have the right to terminate this Agreement, either in whole or in relation to a particular
Licensed Technology, with immediate effect by written notice to Arrys if Arrys or any of its Affiliates materially breaches any of its obligations under this Agreement and, after receiving written notice from AskAt identifying such material breach
by Arrys in reasonable detail, fails to cure such material breach within [***] from the date of such notice; provided that such [***] period except for breaches of payment obligations shall be extended to [***] if Arrys has commenced and is
continuing good faith efforts to cure such breach but was no able to cure such breach within the initial [***] period. For clarity, in no event shall such [***] period with respect to breaches of payment obligations be extended. 

(b) Insolvency. If, at any time during the Term (i) a case is commenced by or against either Party under Title 11, United States
Code, as amended, or analogous provisions of Applicable Law outside the United States (the “Bankruptcy Code”) and, in the event of an involuntary case under the Bankruptcy Code, such case is not dismissed within [***] after the
commencement thereof, (ii) either Party files for or is subject to the institution of bankruptcy, liquidation or receivership proceedings (other than a case under the Bankruptcy Code), (iii) either Party assigns all or a substantial
portion of its assets for the benefit of creditors, (iv) a receiver or custodian is appointed for either Party’s business, or (v) a substantial portion of either Party’s business is subject to attachment or similar process; then,
in any such case ((i), (ii), (iii), (iv) or (v)), the other Party may terminate this Agreement upon written notice to the extent permitted under Applicable Law. 

  
 37 

 10.4 Disputed Termination Right. If the
non-terminating Party reasonably disputes in good faith the right of the other Party to terminate this Agreement for any reason other than Arrys’s right to terminate for convenience pursuant to
Section 10.2, and such non-terminating Party provides the terminating Party written notice of such dispute with reasonable justification for such dispute within [***] after the terminating Party’s
notice, as applicable, then the terminating Party shall not have the right to terminate this Agreement unless and until a court, in accordance with Article 11, has determined that the terminating Party has the right to terminate this Agreement in
accordance with the terms and conditions set forth herein. It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect. 

10.5 Effects of Termination. 

(a) Upon termination of this Agreement by Arrys under Section 10.2(a), by AskAt under Section 10.3(a), or by either
Party pursuant to Section 10.3(b), the following shall apply (in addition to any other rights and obligations under this Article 10): 

(i) Licenses and Exclusivity. All licenses granted in Article 4 shall terminate and the exclusivity obligations
set forth in Section 4.4 shall terminate; 
 (ii) Arrys Sublicenses. Any existing agreements that contain
a Arrys Sublicense shall terminate and Arrys shall terminate all sublicenses and cause all Affiliates and Arrys’s Sublicensees to cease to Exploit all Licensed Compound and Licensed Product, provided however that, if a Arrys Sublicensee
was not then in breach of its Arrys Sublicense agreement with Arrys and if the actions or failure to act of such Arrys Sublicensee did not give rise to the basis for termination by AskAt, upon written request of such Arrys Sublicensee, such Arrys
Sublicensee and AskAt shall enter into a direct license agreement under the Licensed Technology within the scope of the relevant Arrys Sublicense, on the same terms as set forth in this Agreement and AskAt agrees to negotiate in good faith the final
form of such license agreement; 
 (iii) Confidential Information and Materials. Each Party shall, within [***] of the
termination date, return to the other Party (or as directed by such other Party destroy and certify to such other Party in writing as to such destruction) all of such other Party’s Confidential Information provided by or on behalf of such other
Party hereunder that is in the possession or control of such Party (or any of its Affiliates, sublicensees or subcontractors), except that such Party shall have the right to retain [***] copy of Confidential Information of such other Party strictly
for legal purposes; and 
 (iv) Arrys shall, and shall cause each of its Affiliates and each Arrys Sublicensee to, provide to
AskAt, without any charge, a copy of or reasonable access to any Know-How or Inventions Controlled by Arrys, or any of its Affiliates or any Arrys Sublicensee that were developed, created, conceived or reduced
to practice by or on behalf of such Person in the course of the Development and Commercialization of Licensed Compound and Licensed Product (“Related Know-How and Inventions”). Arrys shall
grant, and cause of its Affiliates and each Arrys Sublicensee that Controls any such Know-How or Inventions to grant to AskAt a non-exclusive, transferable,
sublicenseable, worldwide, royalty free, fully paid up, perpetual and irrevocable license to Exploit the Related Know-How and Inventions Controlled by such Person without any restriction to the extent
Applicable Law permits. Notwithstanding the foregoing, (A) in the event that Arrys, any of its Affiliates or any Sublicensee experiences a Change of Control on or after the Effective Date and prior to the termination of this Agreement, the
Related Know-How and Inventions to be licensed by such Person pursuant to this 

  
 38 

 
Section 10.5(a)(iv) shall be limited to the Related Know-How and Inventions Controlled by such Person prior to such Change of Control and
(B) this Section 10.5(a)(iv) shall not apply in the event of a termination by Arrys pursuant to Section 10.3(b). 

(b) Upon termination of Section 6.1(b) by Arrys pursuant to Section 10.2(b), the license grant set forth in
Section 6.1(b) shall terminate. 
 10.6 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by AskAt are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The
Parties agree that Arrys, as licensee of certain rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the commencement of a
bankruptcy proceeding by or against AskAt under the U.S. Bankruptcy Code, Arrys shall be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property licensed to Arrys and all embodiments of such intellectual
property, which, if not already in Arrys’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon Arrys’s written request therefor, unless AskAt elects to continue to perform all
of its obligations under this Agreement or (b) if not delivered under clause (a), following the rejection of this Agreement by AskAt upon written request therefor by Arrys. 

10.7 Survival. Notwithstanding anything to the contrary, the following provisions shall survive and apply after expiration or
termination of this Agreement in its entirety: Sections 3.6(c) and (d), 6.1, 6.2(b), 6.3 (but solely with respect to Joint Patents), 6.4 (but solely with respect to Joint Patents), 7.3(h), 8.1,
8.2, 8.3, 8.4, 10.5 and 10.7 and Article 1, Article 5, Article 9, Article 11 and Article 12. In addition, the other applicable provisions of Article 5 shall survive such
expiration or termination of this Agreement in its entirety to the extent required to make final reimbursements, reconciliations or other payments incurred or accrued prior to the date of termination or expiration. All provisions not surviving in
accordance with the foregoing shall terminate upon expiration or termination of this Agreement and be of no further force and effect. Termination or expiration of this Agreement for any reason shall not constitute a waiver or release of, or
otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or otherwise, that a Party may have hereunder or that may arise out of or in connection with such termination or expiration. 

ARTICLE 11 
 DISPUTE
RESOLUTION 
 11.1 Disputes. Except as otherwise expressly set forth in this Agreement, disputes of any nature arising under,
relating to, or in connection with this Agreement (“Disputes”) shall be resolved pursuant to this Article 11. 

11.2 Dispute Escalation. In the event of a Dispute between the Parties, the Parties shall first attempt to resolve such Dispute by
negotiation and consultation between themselves. In the event that such Dispute is not resolved on an informal basis within [***] from receipt of the written notice of a Dispute, either party may, by written notice to the other, have such Dispute
referred to the Chief Executive Officer of each Party (or the designee of the Chief Executive 

  
 39 

 
Officer, which designee is required to have decision-making authority on behalf of such Party), who shall attempt to resolve such Dispute by negotiation and consultation for a [***] period
following receipt of such written notice. 
 11.3 Arbitration. In the event the Parties have not resolved such Dispute within [***]
of receipt of the written notice referring such Dispute pursuant to Section 11.2, either Party may at any time after such [***] period submit such Dispute to be finally settled by arbitration administered in accordance with the
procedural rules of the American Arbitration Association (the “AAA”) in effect at the time of submission, as modified by this Section 11.3. The arbitration shall be governed by the Laws of the State of New York. The
arbitration shall be heard and determined by [***] arbitrators who are retired judges or attorneys with at least [***] of relevant experience in the pharmaceutical and biotechnology industry, each of whom shall be impartial and independent. Each
Party shall appoint [***] arbitrator and the [***] arbitrator shall be selected by the [***] Party-appointed arbitrators, or, failing agreement within [***] following appointment of the second arbitrator, by the AAA. Such arbitration shall take
place in New York, New York. The arbitration award so given shall, absent manifest error, be a final and binding determination of the Dispute, shall be fully enforceable in any court of competent jurisdiction, and shall not include any damages
expressly prohibited by Section 8.4. Fees, costs and expenses of arbitration are to be divided by the Parties in the following manner: each Party shall pay for the arbitrator it chooses and the Parties shall share payment for the third
arbitrator. Except in a proceeding to enforce the results of the arbitration or as otherwise required by law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written
consent of both Parties. 
 11.4 Injunctive Relief. Notwithstanding the dispute resolution procedures set forth in this Article
11, in the event of an actual or threatened breach of this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief), without first submitting to any
dispute resolution procedures hereunder. 
 11.5 Tolling. 

(a) The Parties agree that all applicable statutes of limitation and time-based defenses (such as estoppel and laches), as well as all time
periods in which a party must exercise rights or perform obligations hereunder, shall be tolled once the dispute resolution procedures set forth in this Article 11 have been initiated and for so long as they are pending, and the Parties shall
cooperate in taking all actions reasonably necessary to achieve such a result. 
 (b) In addition, during the pendency of any Dispute under
this Agreement initiated before the end of any applicable cure period: 
 (i) this Agreement shall remain in full force and
effect, 
 (ii) the provisions of this Agreement relating to termination for material breach with respect to such Dispute
shall not be effective, 
 (iii) the time period for cure under Section 10.3(a) as to any termination notice
given prior to the initiation of arbitration shall be tolled, 
 (iv) any time periods to exercise rights or perform
obligations shall be tolled; and 

  
 40 

 (v) neither Party shall issue a notice of termination pursuant to this
Agreement based on the subject matter of the arbitration, until the arbitral tribunal has confirmed the material breach and the existence of the facts claimed by a Party to be the basis for the asserted material breach; provided, that if such
breach can be cured by the taking of specific remedial actions, the defaulting Party shall have a reasonable period of time to undertake and complete such remedial actions before any such notice of termination can be issued. Further, with respect to
any time periods that have run during the pendency of the Dispute, the applicable Party shall have a reasonable period of time to exercise any rights or perform any obligations affected by the running of such time periods. 

ARTICLE 12 

MISCELLANEOUS 
 12.1
Entire Agreement; Amendment. This Agreement, including the Exhibits and Schedules hereto, set forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings between the Parties existing as of the Effective Date with respect to the subject matter hereof. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this
Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 
 12.2 Force
Majeure. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented or delayed by force majeure and the nonperforming Party promptly provides notice of the
prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure
shall mean conditions beyond the control of the Parties, including an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, failure or default of public utilities or common
carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe, and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence, and
prudence that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of undertaking under the same or similar circumstances). 

12.3 Notices and Reports. Any notice and report required or permitted to be given under this Agreement shall be in writing, shall
specifically refer to this Agreement, and shall be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 12.3, and shall be
deemed to have been given for all purposes (a) when received, if hand-delivered or sent by a reputable international expedited delivery service, or (b) [***] (such days to be determined with respect to Business Days of the addressee) after
mailing, if mailed by first class certified or registered mail, postage prepaid, return receipt requested. This Section 12.3 is not intended to govern the
day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

  
 41 

			
	If to AskAt:	  	 AskAt Inc.
 Att: [***]

[***]
 [***], Nagoya, 466-0841 Japan

		
	If to Arrys:	  	c/o OrbiMed Advisors, LLC 
601 Lexington Avenue 
New York, NY 10022 USA 
Attn: [***]
		
	With a copy to (which shall not constitute notice):	  	Goodwin Procter LLP 
100 Northern Avenue 
Boston, MA 02109 USA 
Attn: [***]

 12.4 No Strict Construction; Headings. This Agreement has been prepared jointly and shall not be
strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article and Section in
this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 

12.5 Interpretation. Whenever any provision of this Agreement uses the term “including” (or “includes”), such term
shall be deemed to mean “including without limitation” (or “includes without limitations”). “Herein,” “hereby,” “hereunder,” “hereof” and other equivalent words refer to this Agreement
as an entirety and not solely to the particular portion of this Agreement in which any such word is used. The term “will” has the same meaning as the term “shall”. The term “or” means “and/or” hereunder. All
definitions set forth herein shall be deemed applicable whether the words defined are used herein in the singular or the plural. Unless otherwise provided, all references to Sections and Exhibits in this Agreement are to Sections and Exhibits of
this Agreement. References to any Sections include Sections and subsections that are part of the related Section (e.g., a section numbered “Section 3.2” would be part of “Section 3”, and references to
“Section 3.2” would also refer to material contained in the subsection described as “Section 3.2(a)”). Unless otherwise stated, dollar amounts set forth in this Agreement are U.S. dollars. 

12.6 Assignment. Neither Party may assign or transfer (whether by operation of Applicable Law or otherwise) this Agreement or any
rights or obligations hereunder without the prior written consent of the other, except that following prior written notice to the other Party, (a) Arrys may make such an assignment without AskAt’s consent to an Affiliate or to a successor
to all or substantially all of the business or assets to which this Agreement relates, whether in a merger, sale of stock, sale of assets, reorganization or other transaction and (b) AskAt may make such an assignment without Arrys’s
consent to a successor to all or substantially all of the business or assets to which this Agreement relates, including the assets related to the Licensed Compound or Licensed Products, whether in a merger, sale of stock, sale of assets,
reorganization or other transaction. Any permitted successor or assignee of rights or obligations hereunder shall expressly assume performance of such rights or obligations (and in any event, any Party assigning this Agreement to an Affiliate shall
remain bound by the terms and 

  
 42 

 
conditions hereof and any Party assigning this Agreement to a Third Party other than Affiliate shall remain bound by the terms and conditions of Article 9). Any permitted assignment shall
be binding on and inure to the benefit of the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 12.6 shall be null, void and of no legal effect. 

12.7 Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its
Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any
breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such
Party’s Affiliate. 
 12.8 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and
to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 12.9
Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by an arbitrator or by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered
severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives
contemplated by the Parties when entering into this Agreement may be realized. 
 12.10 No Waiver. Any delay in enforcing a
Party’s rights under this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an
express written and signed waiver relating to a particular matter for a particular period of time. 
 12.11 Independent Contractors.
Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein shall be construed to
create the relationship of partners, principal and agent, or joint-venture partners between the Parties. 
 12.12 Counterparts. This
Agreement may be executed in one (1) or more counterparts, by facsimile, pdf or other electronic format, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

12.13 Choice of Law. This Agreement shall be governed by, and enforced and construed in accordance with, the laws of the State of New
York, without regard to its conflicts of law provisions. 
 [Signature Page Follows] 

  
 43 

 IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized
representatives as of the Effective Date. 
  

			
	ASKAT INC.

 
			
		
	By:	 	/s/ Akihiro Furuta

 
			
	Name:	 	Akihiro Furuta
	Title:	 	President
	
	ARRYS THERAPEUTICS, INC.

 
			
		
	By:	 	/s/ Iain Dukes

 
			
	Name:	 	Iain Dukes
	Title:	 	President and Chief Executive Officer

 EXHIBIT A 

LICENSED PATENTS 

COMPOSITION PATENTS & TREATMENT PATENTS 
  

							
	 Patent
	  	 International publication No.
	  	 International filing date

(Expiration date w/o PTE*)
	  	 Country

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 [***] 

 COMPOSITION PATENTS for AAT-007 

[***] 
  

							
	 Country
	  	 Application No.
	  	 Patent No.
	  	 IPM Status

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 COMPOSITION PATENTS for AAT-007 Polymorph 

[***] 
  

							
	 Country
	  	 Application No.
	  	 Patent No.
	  	 IPM
Status

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 EXHIBIT B 

DEVELOPMENT PLAN 
 [***] 

 SCHEDULE 1.97 

CERTAIN REGULATORY MATERIALS 
  

													
	 Country
	  	 IND No.
	  	 Drug
	  	 Sponsor
	  	 Indication
	  	 Phase
	  	 Status

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 SCHEDULE 7.2(A) 

IP CONFLICTS 
 None. 

 SCHEDULE 7.2(e)(i) 

LIST OF LICENSE AGREEMENTS 
  

									
	 Title
	  	 Compound
	  	 Company
	  	 Date
	  	 Description

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 [***] 
 LIST OF ACTIVE
COLLABORATION AGREEMENTS 
  

											
	 Agreement
	  	 Name
	  	 Affiliation
	  	 Study
	  	 Compound
	  	 Date

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 [***] 

 SCHEDULE 7.2(e)(ii) 

 

									
	 Title
	  	 Compound
	  	 Parties
	  	 Date
	  	 Description

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

 [***] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH
“[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. 

AMENDMENT NO. 1 TO LICENSE AGREEMENT 

THIS AMENDMENT NO. 1 TO LICENSE AGREEMENT (this “Amendment No. 1”) is entered into as of December 18,
2018 (the “Amendment No. 1 Effective Date”), by and between Arrys Therapeutics, Inc., (“Arrys”) and AskAt, Inc. (“AskAt”). Capitalized terms used herein but not defined herein
shall have the same meaning as set forth in the Agreement (as defined below). 
 WHEREAS, Arrys and AskAt entered into that certain
License Agreement between them, dated as of December 14, 2017 (the “Agreement”); and 
 WHEREAS, pursuant to
Section 12.1 of the Agreement, the Parties wish to amend the Agreement as set forth herein. 
 NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties do hereby amend the Agreement as follows: 
  

	 	1.	 Amendment. Exhibit B to the Agreement is hereby amended by replacing the phrase “[***]” with
“[***]”. 

  

	 	2.	 Controlling Nature; Modification; No Other Changes. Upon the execution of this Amendment No. 1 by
an authorized representative of each Party, the Agreement shall be amended in accordance herewith, and this Amendment No. 1 shall form a part of the Agreement for all purposes. Except as expressly amended by this Amendment No. 1, all terms
set forth in the Agreement shall remain the same and shall remain in full force and effect. 

  

	 	3.	 Choice of Law. This Amendment No. 1 shall be governed by, and enforced and construed in accordance
with, the laws of the State of New York, without regard to its conflicts of law provisions. 

  

	 	4.	 Counterparts. This Amendment No. 1 may be executed in one (1) or more counterparts, by
facsimile, pdf or other electronic format, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

[Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, each Party has caused this Amendment No. 1 to be executed by its duly
authorized representative as of the Amendment No. 1 Effective Date. 
  

									
	ARRYS THERAPEUTICS, INC.	 		 	ASKAT, INC.
					
	By:	 	 /s/ Iain Dukes
	 		 	By:	 	 /s/ Akihiro Furuta

									
	Name:	 	Iain Dukes	 		 	Name:	 	Akihiro Furuta
	Title:	 	President and Chief Executive Office	 		 	Title:	 	President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]